エビデンスに基づいた 胆道癌診療ガイドライン 改訂第3版

出版社: 医学図書出版
著者:
発行日: 2019-06-30
分野: 臨床医学:外科  >  消化器外科学
ISBN: 9784865173239
電子書籍版: 2019-06-30 (改訂第3版第2刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:約3営業日

3,850 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,695 円(税込)

商品紹介

予防・疫学から診断、胆道ドレナージ、外科治療、化学療法、放射線療法、病理までを、Q&A形式で解説。胆道癌の日常臨床において判断に苦慮する多くの選択肢についての問題を取り上げた改訂第3版。

目次

  • 第I章.胆道癌診療ガイドラインの目的・使用法・作成法

    第II章.診療アルゴリズム
    1.診断アルゴリズム
    2.治療アルゴリズム

    第III章.予防・疫学
    CQ1 胆道癌の危険因子はどのようなものか?
    CQ2 膵・胆管合流異常に予防的手術は行うべきか?
    CQ3 無症状胆嚢胆石症に胆嚢摘出術は行うべきか?
    CQ4 どのような胆嚢ポリープに対して癌を疑うべきか?

    第IV章.診断
    CQ5 胆道癌を疑う臨床症状は?
    CQ6 胆道癌診断のファーストステップとして行うべき検査は?
    CQ7 胆管癌診断のセカンドステップとして行うべき検査は?
    CQ8 胆管癌診断のサードステップにはどのような検査があるか?
    CQ9 胆嚢癌診断のセカンドステップとしてまず行うべき検査は?
    CQ10 胆嚢癌診断のサードステップにはどのような検査があるか?
    CQ11 乳頭部癌診断のセカンドステップとして行うべき検査は?
    CQ12 乳頭部癌診断のサードステップにはどのような検査があるか?
    CQ13 胆管癌、胆嚢癌が疑われる症例に治療前生検または細胞診は行うべきか?

    第V章.胆道ドレナージ
    CQ14 黄疸患者に術前胆道ドレナージは行うべきか?
    CQ15 遠位胆管閉塞に対する術前胆道ドレナージは何を行うべきか?
    CQ16 肝門部胆管閉塞に対する術前胆道ドレナージは何を行うべきか?
    CQ17 術前胆道ドレナージ中の発熱にはどのように対応すべきか?
    CQ18 術前外瘻ドレナージ患者に胆汁監視培養は行うべきか?
    CQ19 術前外瘻ドレナージ患者に胆汁返還は行うべきか?
    CQ20 切除不能遠位胆管閉塞に対する胆管ステントは何を選択すべきか?
    CQ21 切除不能肝門部胆管閉塞に対する胆管ステントは何を選択すべきか?

    第VI章.外科治療
    CQ22 切除不能胆道癌はどのようなものか?
    CQ23 術前門脈塞栓術はどのような症例に行うべきか?
    CQ24 術前の残肝予備能評価はどのように行うべきか?
    CQ25 血管浸潤例に対して血管合併切除は行うべきか?
    CQ26 肝葉切除を伴う膵頭十二指腸切除(いわゆる major HPD)は行うべきか?
    CQ27 胆嚢癌を疑う症例には腹腔鏡下手術ではなく開腹手術を行うべきか?
    CQ28 肝外胆管に直接浸潤のない胆嚢癌に予防的肝外胆管切除は行うべきか?
    CQ29 肝浸潤を疑う胆嚢癌にはどのような肝切除を行うべきか?
    CQ30 胆嚢摘出術後に深達度ss以上の胆嚢癌が判明した場合に追加切除を行うべきか?
    CQ31 十二指腸乳頭部腫瘍に局所的乳頭部切除術(外科的治療を含む)は行うべきか?
    CQ32 術中胆管切離断端上皮内癌陽性例に胆管の追加切除も行うべきか?
    CQ33 胆管癌切除後の予後因子はどのようなものか?
    CQ34 胆嚢癌切除後の予後因子はどのようなものか?
    CQ35 乳頭部癌切除後の予後因子はどのようなものか?
    CQ36 胆道癌手術は手術数の多い施設で行うべきか?

    第VII章.化学療法
    CQ37 切除不能胆道癌に対するファーストラインの化学療法は何か?
    CQ38 切除不能胆道癌に対するセカンドラインの化学療法は何か?
    CQ39 術後補助化学療法は行うべきか?
    CQ40 閉塞性黄疸に対する化学療法はいつ開始すべきか?

    第VIII章.放射線治療
    CQ41 切除不能胆道癌に放射線治療、または化学放射線療法は行うべきか?
    CQ42 胆道癌切除例に術後放射線治療、または術後化学放射線療法は行うべきか?
    CQ43 胆管癌の治療として,photodynamic therapyは行うべきか?

    第IX章.病理
    CQ44 胆道における腫瘍類似病変はどのようなものか?
    CQ45 胆道のIPNB, BiIIN, dysplasiaはどのようなものか?

    文献検索式(データベース、検索年限、検索式、検索件数)

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第II章. 診療アルゴリズム

P.10 掲載の参考文献
1) 島田光生, 神澤輝実, 安藤久實, 須山正文, 森根裕二, 森大樹. 膵・胆管合流異常の診療ガイドライン (日本膵・胆管合流異常研究会・日本胆道学会編). 胆道 2012 ; 26 : 678-690.
2) 山田眞一郎, 島田光生, 森根裕二. 胆管癌の危険因子. 日本臨牀 2015 ; 73 増 3 膵癌・胆道癌 : 618-621.
3) Li Y, Wei J, Zhao Z, You T, Zhong M. Pancreaticobiliary maljunction is associated with common bile duct carcinoma : a meta-analysis. ScientificWorldJournal 2013 ; 2013 : 618670.
4) 有坂好史, 竹中完, 塩見英之, 東健. 胆嚢ポリープの診断と取扱い. 日消誌 2015 ; 112 : 444-455.
5) Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma : a systematic review of the current literature. J Am Coll Surg 2009 ; 208 : 134-147.
6) DeOliveira ML, Cunningham SC, Cameron JL, Kamanger F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma : thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007 ; 245 : 755-762.
7) Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-140.
8) Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder : results of the French surgical association survey. Ann Surg 1994 ; 219 : 275-280.
9) Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003 ; 4 : 167-176.
10) Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades : a single-institution experience. Arch Surg 2009 ; 144 : 441-447.
11) Tran TB, Norton JA, Ethun CG, Pawlik TM, Buettner S, Schmidt C, et al. Gallbladder cancer presenting with jaundice : uniformly fatal or still potentially curable? J Gastrointest Surg 2017 ; 21 : 1245-1253.
12) 三好広尚, 乾和郎, 芳野純治, 服部昌志, 若林貴夫, 奥嶋一武, 他. 胆嚢癌の超音波診断の現況と問題点. 肝胆膵 2006 ; 53 : 201-204.
13) Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients : implications for surgical strategy and long-term prognosis. J Gastrointest Surg 2010 ; 14 : 379-387.
15) Kamisawa T, Tu Y, Egawa N, Nakajima H, Horiguchi S, Tsuruta K, et al. Clinicopathologic features of ampullary carcinoma without jaundice. J Clin Gastroenterol 2006 ; 40 : 162-166.
16) Cha JM, Kim MH, Lee SK, Seo DW, Lee SS, Lee JH, et al. Clinicopathological review of 61 patients with early bile duct cancer. Clin Oncol (R Coll Radiol) 2006 ; 18 : 669-677.
17) Stepien M, Fedirko V, Duarte-Salles T, Ferrari P, Freisling H, Trepo E, et al. Prospective association of liver function biomarkers with development of hepatobiliary cancers. Cancer Epidemiol 2016 ; 40 : 179-187.
18) 皆川紀剛, 山口幸二. 膵癌・胆道癌の腫瘍マーカー. 成人病と生活習慣病 2011 ; 41 : 654-660.
19) Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 2006 ; 11 : 913-922.
20) Inui K, Yoshino J, Miyoshi H. Diagnosis of gallbladder tumors. Intern Med 2011 ; 50 : 1133-1136.
21) Chen WX, Xie QG, Zhang WF, Zhang X, Hu TT, Xu P, et al. Multiple imaging techniques in the diagnosis of ampullary carcinoma. Hepatobiliary Pancreat Dis Int 2008 ; 7 : 649-653.
22) Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma : expert consensus statement. HPB (Oxford) 2015 ; 17 : 691-699.
23) Ray CE Jr, Lorenz JM, Burke CT, Darcy MD, Fidelman N, Greene FL, et al. ACR Appropriateness Criteria radiologic management of benign and malignant biliary obstruction. J Am Coll Radiol 2013 ; 10 : 567-574.
24) Ruys AT, van Beem BE, Engelbrecht MR, Bipat S, Stoker J, Van Gulik TM. Radiological staging in patients with hilar cholangiocarcinoma : a systematic review and meta-analysis. Br J Radiol 2012 ; 85 : 1255-1262.
25) Okuda Y, Taura K, Seo S, Yasuchika K, Nitta T, Ogawa K, et al. Usefulness of operative planning based on 3-dimensional CT cholangiography for biliary malignancies. Surgery 2015 ; 158 : 1261-1271.
26) Sun N, Xu Q, Liu X, Liu W, Wang J. Comparison of preoperative evaluation of malignant low-level biliary obstruction using plain magnetic resonance and coronal liver acquisition with volume acceleration technique alone and in combination. Eur J Med Res 2015 ; 20 : 92-102.
27) American Society for Gastrointestinal Endoscopy (ASGE) Standards of Practice Committee, Anderson MA, Appalaneni V, Ben-Menachem T, Decker GA, Early DS, Evans JA, et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc 2013 ; 77 : 167-174.
28) Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 2011 ; 46 : 242-248.
29) Kawashima H, Itoh A, Ohno E, Itoh Y, Ebata T, Nagino M, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma : a retrospective study of efficacy and risk factors related to complications. Ann Surg 2013 ; 257 : 121-127.
30) Tamada K, Ushio J, Sugano K. Endoscopic diagnosis of extrahepatic bile duct carcinoma : advances and current limitations. World J Clin Oncol 2011 ; 2 : 203-216.
31) Osanai M, Itoi T, Igarashi Y, Tanaka K, Kida M, Maguchi H, et al. Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension : a prospective multicenter study. Endoscopy 2013 ; 45 : 635-642.
32) Nishikawa T, Tsuyuguchi T, Sakai Y, Sugiyama H, Miyazaki M, Yokosuka O. Comparison of the diagnostic accuracy of peroral video-cholangioscopic visual findings and cholangioscopy-guided forceps biopsy findings for indeterminate biliary lesions : a prospective study. Gastrointest Endosc 2013 ; 77 : 219-226.
33) Manta R, Frazzoni M, Conigliaro R, Maccio L, Melotti G, Dabizzi E, et al. SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions : a single-center, prospective, cohort study. Surg Endosc 2013 ; 27 : 1569-1572.
34) Ramchandani M, Reddy DN, Lakhtakia S, Tandan M, Maydeo A, Chandrashekhar TS, et al. Per oral cholangiopancreatoscopy in pancreatico biliary diseases : expert consensus statements. World J Gastroenterol 2015 ; 21 : 4722-4734.
35) Alper E, Arabul M, Buyrac Z, Baydar B, Ustundag Y, Celik M, et al. The use of radial endosonography findings in the prediction of cholangiocarcinoma in cases with distal bile duct obstructions. Hepatogastroenterology 2013 ; 60 : 678-683.
36) Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures : a systematic review and meta-analysis. Gastrointest Endosc 2015 ; 81 : 168-176.
37) Annunziata S, Caldarella C, Pizzuto DA, Galiandro F, Sadeghi R, Giovanella L, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma : a meta-analysis. Biomed Res Int 2014 : 247693.
38) Cheng MF, Wang HP, Tien YW, Liu KL, Yen RF, Tzen KY, et al. Usefulness of PET/CT for the differentiation and characterization of periampullary lesions. Clin Nucl Med 2013 : 38 : 703-708.
40) Kim SJ, Lee JM, Lee JY, Choi JY, Kim SH, Han JK, et al. Accuracy of preoperative T-staging of gallbladder carcinoma using MDCT. AJR Am J Roentgenol 2008 ; 190 : 74-80.
41) Schwartz LH, Lefkowitz RA, Panicek DM, Coakley FV, Jarnagin W, Dematteo R, et al. Breath-hold magnetic resonance cholangiopancreatography in the evaluation of malignant pancreaticobiliary obstruction. J Comput Assist Tomogr 2003 ; 27 : 307-314.
42) Kim JH, Kim TK, Eun HW, Kim BS, Lee MG, Kim PN, et al. Preoperative evaluation of gallbladder carcinoma : efficacy of combined use of MR imaging, MR cholangiography, and contrast-enhanced dual-phase three-dimensional MR angiography. J Magn Reson Imaging 2002 ; 16 : 676-684.
43) Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, et al. Liver tumors : comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996 ; 200 : 59-67.
44) Lee NK, Kim S, Kim TU, Kim DU, Seo HI, Jeon TY. Diffusion-weighted MRI for differentiation of benign from malignant lesions in the gallbladder. Clin Radiol 2014 ; 69 : e78-85.
45) Kitazume Y, Taura S, Nakaminato S, Noguchi O, Masaki Y, Kasahara I, et al. Diffusion-weighted magnetic resonance imaging to differentiate malignant from benign gallbladder disorders. Eur J Radiol 2016 ; 85 : 864-873.
46) Azuma T, Yoshikawa T, Araida T, Takasaki K. Differential diagnosis of polypoid lesions of the gallbladder by endoscopic ultrasonography. Am J Surg 2001 ; 181 : 65-70.
47) Cheon YK, Cho WY, Lee TH, Cho YD, Moon JH, Lee JS, et al. Endoscopic ultrasonography does not differentiate neoplastic from non-neoplastic small gallbladder polyps. World J Gastroenterol 2009 ; 15 : 2361-2366.
48) Choi WB, Lee SK, Kim MH, Seo DW, Kim HJ, Kim DI, et al. A new strategy to predict the neoplastic polyps of the gallbladder based on a scoring system using EUS. Gastrointest Endosc 2000 ; 52 : 372-379.
49) Jang JY, Kim SW, Lee SE, Hwang DW, Kim EJ, Lee JY, et al. Differential diagnostic and staging accuracies of high resolution ultrasonography, endoscopic ultrasonography, and multidetector computed tomography for gallbladder polypoid lesions and gallbladder cancer. Ann Surg 2009 ; 250 : 943-949.
50) Ramchandani M, Reddy DN, Gupta R, Lakhtakia S, Tandan M, Darisetty S, et al. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions : a single-center, prospective study. Gastrointest Endosc 2011 ; 74 : 511-519.
51) Tsukada K, Takada T, Miyazaki M, Miyakawa S, Nagino M, Kondo S, et al. Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008 ; 15 : 31-40.
52) Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 2010 ; 45 : 560-566.
53) Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma : a prospective study compared with conventional imaging. Am J Gastroenterol 2008 ; 103 : 1145-1151.
54) Kitajima K, Murakami K, Kanegae K, Tamaki N, Kaneta T, Fukuda H, et al. Clinical impact of whole body FDG-PET for recurrent biliary cancer : a multicenter study. Ann Nucl Med 2009 ; 23 : 709-715.
55) Kumar R, Sharma P, Kumari A, Halanaik D, Malhotra A. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma. Clin Nucl Med 2012 ; 37 : 431-435.
56) Yamaguchi K, Enjoji M, Kitamura K. Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 1990 ; 36 : 588-592.
57) Lee M, Kim MJ, Park MS, Choi JY, Chung YE. Using multi-detector-row CT to diagnose ampullary adenoma or adenocarcinoma in situ. Eur J Radiol 2011 ; 80 : e340-345.
58) Trikudanathan G, Njei B, Attam R, Arain M, Shaukat A. Staging accuracy of ampullary tumors by endoscopic ultrasound : meta-analysis and systematic review. Dig Endosc 2014 ; 26 : 617-626.
59) Menzel J, Hoepffner N, Sulkowski U, Reimer P, Heinecke A, Poremba C, et al. Polypoid tumors of the major duodenal papilla : preoperative staging with intraductal US, EUS, and CT - a prospective, histopathologically controlled study. Gastrointest Endosc 1999 ; 49 : 349-357.
60) Itoh A, Goto H, Naitoh Y, Hirooka Y, Furukawa T, Hayakawa T. Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 1997 ; 45 : 251-260.
61) Ito K, Fujita N, Noda Y, Kobayashi G, Horaguchi J, Takasawa O, et al. Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US : a prospective and histopathologically controlled study. Gastrointest Endosc 2007 ; 66 : 740-747.
62) Sperti C, Pasquali C, Fiore V, Bissoli S, Chierichetti F, Liessi G, et al. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms. Am J Surg 2006 ; 191 : 743-748.
P.17 掲載の参考文献
1) Yokoyama Y, Nishio H, Ebata T, Igami T, Sugawara G, Nagino M. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 2010 ; 97 : 1260-1268.
2) Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection : methodology and clinical associations. Surgery 2000 ; 127 : 512-519.
3) Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003 ; 237 : 686-693.
4) Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001 ; 234 : 507-517.
5) Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, et al. Gallbladder cancer (GBC) : 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 2008 ; 98 : 485-489.
7) Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma : a systematic review. HPB (Oxford) 2014 ; 16 : 297-303.
8) Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013 ; 100 : 274-283.
9) Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma : results of an Italian multicenter analysis of 440 patients. Arch Surg 2012 ; 147 : 26-34.
10) Kennedy TJ, Yopp A, Qin Y, Zhao B, Guo P, Liu F, et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009 ; 11 : 445-451.
11) Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, van Klaveren D, Allen PJ, et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma : development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg 2016 ; 223 : 321-331.
12) Takahashi Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 2010 ; 97 : 1860-1866.
13) Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage : a propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 2017 ; 161 : 394-404.
14) Higuchi R, Yazawa T, Uemura S, Izumo W, Chaudhary RJ, Furukawa T, et al. ENBD is associated with decreased tumor dissemination compared to PTBD in perihilar cholangiocarcinoma. J Gastrointest Surg 2017 ; 21 : 1506-1514.
15) Noie T, Sugawara Y, Imamura H, Takayama T, Makuuchi M. Selective versus total drainage for biliary obstruction in the hepatic hilus : an experimental study. Surgery 2001 ; 130 : 74-81.
16) Ishizawa T, Hasegawa K, Sano K, Imamura H, Kokudo N, Makuuchi M. Selective versus total biliary drainage for obstructive jaundice caused by a hepatobiliary malignancy. Am J Surg 2007 ; 193 : 149-154.
17) Higuchi R, Yamamoto M. Indications for portal vein embolization in perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014 ; 21 : 542-549.
18) Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-140.
19) Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007 ; 356 : 1545-1559.
20) Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford) 2013 ; 15 : 492-503.
21) Chen W, Ke K, Chen YL. Combined portal vein resection in the treatment of hilar cholangiocarcinoma : a systematic review and meta-analysis. Eur J Surg Oncol 2014 ; 40 : 489-495.
22) Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma : an audit of 50 consecutive cases. Ann Surg 2010 ; 252 : 115-123.
23) Noji T, Tsuchikawa T, Okamura K, Nakamura T, Tamoto E, Shichinohe T, et al. Resection and reconstruction of the hepatic artery for advanced perihilar cholangiocarcinoma : result of arterioportal shunting. J Gastrointest Surg 2015 ; 19 : 675-681.
24) Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma : a single-center review of 85 consecutive patients. Ann Surg 2012 ; 256 : 297-305.
25) Aoki T, Sakamoto Y, Kohno Y, Akamatsu N, Kaneko J, Sugawara Y, et al. Hepatopancreaticoduodenectomy for biliary cancer : strategies for near-zero operative mortality and acceptable long-term outcome. Ann Surg 2018 ; 267 : 332-337.
26) Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Onoe S. Major hepatopancreatoduodenectomy with simultaneous resection of the hepatic artery for advanced biliary cancer. Langenbecks Arch Surg 2016 ; 401 : 471-478.
27) Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma : long-term results. World J Surg 2008 ; 32 : 1067-1074.
28) Lim CS, Jang JY, Lee SE, Kang MJ, Kim SW. Reappraisal of hepatopancreatoduodenectomy as a treatment modality for bile duct and gallbladder cancer. J Gastrointest Surg 2012 ; 16 : 1012-1018.
29) Tsukahara T, Ebata T, Shimoyama Y, Yokoyama Y, Igami T, Sugawara G, et al. Residual carcinoma in situ at the ductal stump has a negative survival effect : an analysis of early-stage cholangiocarcinomas. Ann Surg 2017 ; 266 : 126-132.
30) Yoon YS, Han HS, Cho JY, Choi Y, Lee W, Jang JY, et al. Is laparoscopy contraindicated for gallbladder cancer? : a 10-year prospective cohort study. J Am Coll Surg 2015 ; 221 : 847-853.
31) Jang JY, Heo JS, Han Y, Chang J, Kim JR, Kim H, et al. Impact of type of surgery on survival outcome in patients with early gallbladder cancer in the era of minimally invasive surgery : oncologic safety of laparoscopic surgery. Medicine (Baltimore) 2016 ; 95 : e3675.
32) Goetze TO, Paolucci V. Prognosis of incidental gallbladder carcinoma is not influenced by the primary access technique : analysis of 837 incidental gallbladder carcinomas in the German registry. Surg Endosc 2013 ; 27 : 2821-2828.
34) Tsukada K, Hatakeyama K, Kurosaki I, Uchida K, Shirai Y, Muto T, et al. Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. Surgery 1996 ; 120 : 816-821.
35) Shimizu Y, Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, et al. Should the extrahepatic bile duct be resected for locally advanced gallbladder cancer? Surgery 2004 ; 136 : 1012-1017.
36) Horiguchi A, Miyakawa S, Ishihara S, Miyazaki M, Ohtsuka M, Shimizu H, et al. Gallbladder bed resection or hepatectomy of segments 4a and 5 for pT2 gallbladder carcinoma : analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 518-524.
37) Choi SB, Han HJ, Kim WB, Song TJ, Suh SO, Choi SY. Surgical strategy for T2 and T3 gallbladder cancer : is extrahepatic bile duct resection always necessary? Langenbecks Arch Surg 2013 ; 398 : 1137-1144.
38) Higuchi R, Ota T, Araida T, Kajiyama H, Yazawa T, Furukawa T, et al. Surgical approaches to advanced gallbladder cancer : a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol 2014 ; 21 : 4308-4316.
39) Ha TY, Yoon YI, Hwang S, Park YJ, Kang SH, Jung BH, et al. Effect of reoperation on long-term outcome of pT1b/T2 gallbladder carcinoma after initial laparoscopic cholecystectomy. J Gastrointest Surg 2015 ; 19 : 298-305.
40) Igami T, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, et al. Combined extrahepatic bile duct resection for locally advanced gallbladder carcinoma : does it work? World J Surg 2015 ; 39 : 1810-1817.
41) Wakai T, Shirai Y, Sakata J, Tsuchiya Y, Nomura T, Hatakeyama K. Surgical outcomes of minor hepatectomy for locally advanced gallbladder carcinoma. Hepatogastroenterology 2012 ; 59 : 2083-2088.
42) 伊藤啓, 藤田直孝, 野田裕, 小林剛, 洞口淳, 越田真介, 他. 十二指腸乳頭部腫瘍に対する内視鏡を用いた進展度診断. 胆と膵 2012 ; 33 : 233-241.
43) Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial. JAMA 2012 ; 308 : 147-156.
44) Primrose JN, Fox RP, Palmer DH, Prasad R, Mirza D, Anthoney A, et al. Adjuvant capecitabine for biliary tract cancer : the BILCAP randomized study. J Clin Oncol 2017 ; 35 suppl : 4006.
45) Almadi MA, Barkun A, Martel M. Plastic vs self-expandable metal stents for palliation in malignant biliary obstruction : a series of meta-analyses. Am J Gastroenterol 2017 ; 112 : 260-273.
46) Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma : covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol 2010 ; 33 : 97-106.
47) Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-1281.
48) Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 2010 ; 103 : 469-474.
49) Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer : a Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). 2018 Gastrointestinal Cancers Symposium. #205
50) Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, Seo S, et al : Randomized, phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). 2018 ESMO annual meeting #6150
51) Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017 ; 357 : 409-413.
52) Nanashima A, Nagayasu T. Current status of photodynamic therapy in digestive tract carcinoma in Japan. Int J Mol Sci 2015 ; 16 : 3434-3440.
53) Hong MJ, Cheon YK, Lee EJ, Lee TY, Shim CS. Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma. Gut Liver 2014 ; 8 : 318-323.

第III章. 予防・疫学

P.23 掲載の参考文献
1) Borena W, Edlinger M, Bjorge T, Haggstrom C, Lindkvist B, Nagel G, et al. A prospective study on metabolic risk factors and gallbladder cancer in the metabolic syndrome and cancer (Me-Can) collaborative study. PLoS One 2014 ; 9 : e89368.
2) Guo P, Xu C, Zhou Q, Zhou J, Zhao J, Si Z, et al. Number of parity and the risk of gallbladder cancer : a systematic review and dose-response meta-analysis of observational studies. Arch Gynecol Obstet 2016 ; 293 : 1087-1096.
3) Gu J, Yan S, Wang B, Shen F, Cao H, Fan J, et al. Type 2 diabetes mellitus and risk of gallbladder cancer : a systematic review and meta-analysis of observational studies. Diabetes Metab Res Rev 2016 ; 32 : 63-72.
4) Kamisawa T, Kuruma S, Tabata T, Chiba K, Iwasaki S, Koizumi S, et al. Pancreaticobiliary maljunction and biliary cancer. J Gastroenterol 2015 ; 50 : 273-279.
5) Morine Y, Shimada M, Takamatsu H, Araida T, Endo I, Kubota M, et al. Clinical features of pancreaticobiliary maljunction : update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci 2013 ; 20 : 472-480.
6) Li Y, Wei J, Zhao Z, You T, Zhong M. Pancreaticobiliary maljunction is associated with common bile duct carcinoma : a meta-analysis. ScientificWorldJournal 2013 : 618670.
7) Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol 2013 ; 59 : 571-582.
8) Cai H, Kong WT, Chen CB, Shi GM, Huang C, Shen YH, et al. Cholelithiasis and the risk of intrahepatic cholangiocarcinoma : a meta-analysis of observational studies. BMC Cancer 2015 ; 15 : 831.
9) Suzuki Y, Mori T, Yokoyama M, Nakazato T, Abe N, Nakanuma Y, et al. Hepatolithiasis : analysis of Japanese nationwide surveys over a period of 40 years. J Hepatobiliary Pancreat Sci 2014 ; 21 : 617-622.
10) Kubo S, Nakanuma Y, Takemura S, Sakata C, Urata Y, Nozawa A, et al. Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci 2014 ; 21 : 479-488.
11) Kumagai S, Sobue T, Makiuchi T, Kubo S, Uehara S, Hayashi T, et al. Relationship between cumulative exposure to 1, 2-dichloropropane and incidence risk of cholangiocarcinoma among offset printing workers. Occup Environ Med 2016 ; 73 : 545-552.
12) Xia J, Jiang SC, Peng HJ. Association between liver fluke infection and hepatobiliary pathological changes : a systematic review and meta-analysis. PLoS One 2015 ; 10 : e0132673.
13) Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA 1983 ; 250 : 2323-2326.
14) Scott TE, Carroll M, Cogliano FD, Smith BF, Lamorte WW. A case-control assessment of risk factors for gallbladder carcinoma. Dig Dis Sci 1999 ; 44 : 1619-1625.
15) Serra I, Yamamoto M, Calvo A, Cavada G, Baez S, Endoh K, et al. Association of chili pepper consumption, low socioeconomic status and longstanding gallstones with gallbladder cancer in a Chilean population. Int J Cancer 2002 ; 102 : 407-411.
17) Pilgrim CH, Groeschl RT, Christians KK, Gamblin TC. Modern perspectives on factors predisposing to the development of gallbladder cancer. HPB (Oxford) 2013 ; 15 : 839-844.
18) Schnelldorfer T. Porcelain gallbladder : a benign process or concern for malignancy? J Gastrointest Surg 2013 ; 17 : 1161-1168.
19) Nagaraja V, Eslick GD. Systematic review with meta-analysis : the relationship between chronic Salmonella typhi carrier status and gallbladder cancer. Aliment Pharmacol Ther 2014 ; 39 : 745-750.
20) Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer 1992 ; 69 : 2647-2652.
21) Nabatame N, Shirai Y, Nishimura A, Yokoyama N, Wakai T, Hatakeyama K. High risk of gallbladder carcinoma in elderly patients with segmental adenomyomatosis of the gallbladder. J Exp Clin Cancer Res 2004 ; 23 : 593-598.
22) 守慶, 窪川良広, 崔仁煥, 須山正文, 信川文誠. 胆嚢腺筋腫症に合併した胆嚢癌の臨床病理学的検討. 胆道 2010 ; 24 : 675-682.
23) Kaiser A, Jurowich C, Schonekas H, Gebhardt C, Wunsch PH. The adenoma-carcinoma sequence applies to epithelial tumours of the papilla of Vater. Z Gastroenterol 2002 ; 40 : 913-920.
24) Baczako K, Buchler M, Beger HG, Kirkpatrick CJ, Haferkamp O. Morphogenesis and possible precursor lesions of invasive carcinoma of the papilla of Vater : epithelial dysplasia and adenoma. Hum Pathol 1985 ; 16 : 305-310.
25) Takashima M, Ueki T, Nagai E, Yao T, Yamaguchi K, Tanaka M, et al. Carcinoma of the ampulla of Vater associated with or without adenoma : a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions. Mod Pathol 2000 ; 13 : 1300-1307.
26) Howe JR, Klimstra DS, Cordon-Cardo C, Paty PB, Park PY, Brennan MF. K-ras mutation in adenomas and carcinomas of the ampulla of Vater. Clin Cancer Res 1997 ; 3 : 129-133.
27) Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients with familial adenomatous polyposis (FAP) : results of a 10 year prospective study. Gut 2002 ; 50 : 636-641.
P.26 掲載の参考文献
1) 島田光生, 神澤輝実, 安藤久實, 須山正文, 森根裕二, 森大樹. 膵・胆管合流異常の診療ガイドライン (日本膵・胆管合流異常研究会・日本胆道学会編). 胆道 2012 ; 26 : 678-690.
2) Shimada K, Yanagisawa J, Nakayama F. Increased lysophosphatidylcholine and pancreatic enzyme content in bile of patients with anomalous pancreaticobiliary ductal junction. Hepatology 1991 ; 13 : 438-444.
3) Tsuchida A, Itoi T. Carcinogenesis and chemoprevention of biliary tract cancer in pancreaticobiliary maljunction. World J Gastrointest Oncol 2010 ; 2 : 130-135.
4) 森根裕二, 島田光生, 石橋広樹. 膵・胆管合流異常の最前線. 全国集計からみた膵・胆管合流異常. 日消誌 2014 ; 111 : 699-705.
5) Kamisawa T, Kuruma S, Tabata T, Chiba K, Iwasaki S, Koizumi S, et al. Pancreaticobiliary maljunction and biliary cancer. J Gastroenterol 2015 ; 50 : 273-279.
6) 高屋敷吏, 清水宏明, 大塚将之, 加藤厚, 吉富秀幸, 宮崎勝. 膵・胆管合流異常の診断と外科治療. 胆道 2014 ; 28 : 172-179.
7) Funabiki T, Matsubara T, Miyakawa S, Ishihara S. Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy. Langenbecks Arch Surg 2009 ; 394 : 159-169.
8) 石橋広樹, 森根裕二, 森大樹, 島田光生. 胆管非拡張型膵・胆管合流異常は先天性胆道拡張症より胆管癌の発生は少ないのか? -日本膵・胆管合流異常研究会登録症例の解析-胆と膵 2012 ; 33 : 61-65.
9) Yamada S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, et al. Hilar cholangiocarcinoma accompanied by pancreaticobiliary maljunction without bile duct dilatation 20 years after cholecystectomy : report of a case. J Med Invest 2013 ; 60 : 169-173.
10) Matsubara T, Sakurai Y, Zhi LZ, Miura H, Ochiai M, Funabiki T. K-ras and p53 gene mutations in noncancerous biliary lesions of patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 2002 ; 9 : 312-321.
11) 岩橋衆一, 森根裕二, 宇都宮徹, 居村暁, 池本哲也, 森大樹, 他. 胆管非拡張型膵・胆管合流異常に対する術式 : 「分流手術」の立場から. 臨外 2014 ; 69 : 182-186.
12) 高屋敷吏, 大塚将之, 清水宏明, 吉留博之, 加藤厚, 吉富秀幸, 他. 胆道癌合併症例における胆管拡張形式の検討からみた膵・胆管合流異常に対する肝外胆管切除の適応. 胆道 2012 ; 26 : 78-84.
13) 大内田次郎, 千々岩一男. 胆管非拡張型膵・胆管合流異常に対する術式 : 「胆摘のみ」の立場から. 臨外 2014 ; 69 : 178-181.
15) Tsuchida A, Itoi T, Endo M, Kitamura K, Mukaide M, Itokawa F, et al. Pathological features and surgical outcome of pancreaticobiliary maljunction without dilatation of the extrahepatic bile duct. Oncol Rep 2004 ; 11 : 269-276.
16) 太田岳洋, 松下典正, 吾妻司, 新井田達雄, 高崎健. 胆管非拡張型膵・胆管合流異常に対する外科治療 : 胆管切除を行わない立場から. 胆と膵 2004 ; 25 : 41-45.
18) 安藤久實, 金子健一朗. 胆管非拡張型膵胆管合流異常に対する手術術式の検討 : 予防的胆管切除は必要か. 胆と膵 2000 ; 21 : 971-976.
19) 渡辺泰宏, 土岐彰, 野田卓男, 植村貞繁, 戸谷拓二. 肝外胆道全切除 (いわゆる分流手術) とその考え方-小児外科の立場から-. 胆と膵 2001 ; 22 : 489-492.
20) Ando H, Ito T, Nagaya M, Watanabe Y, Seo T, Kaneko K. Pancreaticobiliary maljunction without choledochal cysts in infants and children : clinical features and surgical therapy. J Pediatr Surg 1995 ; 30 : 1658-1662.
21) Tian Y, Wu SD, Zhu AD, Chen DX. Management of type I choledochal cyst in adult : totally laparoscopic resection and Roux-en-Y hepaticoenterostomy. J Gastrointest Surg 2010 ; 14 : 1381-1388.
P.28 掲載の参考文献
1) Gurusamy KS, Samraj K. Cholecystectomy versus no cholecystectomy in patients with silent gallstones. Cochrane Database Syst Rev 2007 ; 24 : CD006230.
2) Shabanzadeh DM, Sorensen LT, Jorgensen T. A prediction rule for risk stratification of incidentally discovered gallstones : results from a large cohort study. Gastroenterology 2016 ; 150 : 156-167.
3) McSherry CK, Ferstenberg H, Calhoun WF, Lahman E, Virshup M. The natural history of diagnosed gallstone disease in symptomatic and asymptomatic patients. Ann Surg 1985 ; 202 : 59-63.
4) Festi D, Reggiani ML, Attili AF, Loria P, Pazzi P, Scaioli E, et al. Natural history of gallstone disease : Expectant management or active treatment? results from a population-based cohort study. J Gastroenterol Hepatol 2010 ; 25 : 719-724.
5) Tewari M. Contribution of silent gallstones in gallbladder cancer. J Surg Oncol 2006 ; 93 : 629-632.
6) Sakorafas GH, Milingos D, Peros G. Asymptomatic cholelithiasis : is cholecystectomy really needed? A critical reappraisal 15 years after the introduction of laparoscopic cholecystectomy. Dig Dis Sci 2007 ; 52 : 1313-1325.
7) Gracie WA, Ransohoff DF. The natural history of silent gallstones : the innocent gallstone is not a myth. N Engl J Med 1982 ; 307 : 798-800.
8) Gurusamy KS, Davidson BR. Surgical treatment of gallstones. Gastroenterol Clin North Am 2010 ; 39 : 229-244.
9) Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide : geographical distribution and risk factors. Int J Cancer 2006 ; 118 : 1591-1602.
10) Lowenfels AB, Walker AM, Althaus DP, Townsend G, Domellof L. Gallstone growth, size, and risk of gallbladder cancer : an interracial study. Int J Epidemiol 1989 ; 18 : 50-54.
11) Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA 1983 ; 250 : 2323-2326.
12) Roa I, Ibacache G, Roa J, Araya J, de Aretxabala X, Munoz S. Gallstones and gallbladder cancer-volume and weight of gallstones are associated with gallbladder cancer : a case-control study. J Surg Oncol 2006 ; 93 : 624-628.
13) Serra I, Yamamoto M, Calvo A, Cavada G, Baez S, Endoh K, et al. Association of chili pepper consumption, low socioeconomic status and longstanding gallstones with gallbladder cancer in a Chilean population. Int J Cancer 2002 ; 102 : 407-411.
15) Towfigh S, McFadden DW, Cortina GR, Thompson JE Jr, Tompkins RK, Chandler C, et al. Porcelain gallbladder is not associated with gallbladder carcinoma. Am Surg 2001 ; 67 : 7-10.
16) Yamagiwa H. Mucosal dysplasia of gallbladder : isolated and adjacent lesions to carcinoma. Jpn J Cancer Res 1989 ; 80 : 238-243.
17) Meirelles-Costa AL, Bresciani CJ, Perez RO, Bresciani BH, Siqueira SA, Cecconello I. Are histological alterations observed in the gallbladder precancerous lesions? Clinics (Sao Paulo) 2010 ; 65 : 143-150.
19) Attili AF, De Santis A, Capri R, Repice AM, Maselli S. The natural history of gallstones : the GREPCO experience. The GREPCO Group. Hepatology 1995 ; 21 : 655-660.
20) 内視鏡外科手術に関するアンケート調査-第12回集計結果報告-. 日内視鏡外会誌 2014 ; 19 : 498-632
21) 石和直樹, 山本裕司, 田中聡一, 山田六平, 和田修幸, 熊切寛, 他. 腹腔鏡下胆嚢摘出術の晩期合併症. 外科 2000 ; 62 : 329-332.
P.29 掲載の参考文献
1) 有坂好史, 竹中完, 塩見英之, 東健. 胆嚢ポリープの診断と取扱い. 日消誌 2015 ; 112 : 444-455.
2) Chijiiwa K, Tanaka M. Polypoid lesion of the gallbladder : indications of carcinoma and outcome after surgery for malignant polypoid lesion. Int Surg 1994 ; 79 : 106-109.
3) Kubota K, Bandai Y, Noie T, Ishizaki Y, Teruya M, Makuuchi M. How should polypoid lesions of the gallbladder be treated in the era of laparoscopic cholecystectomy? Surgery 1995 ; 117 : 481-487.
4) Park JK, Yoon YB, Kim YT, Ryu JK, Yoon WJ, Lee SH, et al. Management strategies for gallbladder polyps : is it possible to predict malignant gallbladder polyps? Gut Liver 2008 ; 2 : 88-94.
5) Kwon W, Jang JY, Lee SE, Hwang DW, Kim SW. Clinicopathologic features of polypoid lesions of the gallbladder and risk factors of gallbladder cancer. J Korean Med Sci 2009 ; 24 : 481-487.
6) Lim SH, Kim D, Kang JH, Song JH, Yang SY, Yim JY, et al. Hepatic fat, not visceral fat, is associated with gallbladder polyps : a study of 2643 healthy subjects. J Gastroenterol Hepatol 2015 ; 30 : 767-774.
7) Corwin MT, Siewert B, Sheiman RG, Kane RA. Incidentally detected gallbladder polyps : Is follow-up necessary? -Long-term clinical and US analysis of 346 patients. Radiology 2011 ; 258 : 277-282.
8) Pedersen MR, Dam C, Rafaelsen SR. Ultrasound follow-up for gallbladder polyps less than 6 mm may not be necessary. Dan Med J 2012 ; 59 : A4503.
9) Yamagiwa H. Mucosal dysplasia of gallbladder : isolated and adjacent lesions to carcinoma. Jpn J Cancer Res 1989 ; 80 : 238-243.
10) Pilgrim CH, Groeschl RT, Christians KK, Gamblin TC. Modern perspectives on factors predisposing to the development of gallbladder cancer. HPB (Oxford) 2013 ; 15 : 839-844.
11) Cha BH, Bae JM. Comparison of clinical outcomes of incidental and non-incidental gallbladder cancers : a singlecenter cross-sectional study. Asian Pac J Cancer Prev 2014 ; 15 : 1281-1283.
12) Matlok M, Migaczewski M, Major P, Pedziwiatr M, Budzynski P, Winiarski M, et al. Laparoscopic cholecystectomy in the treatment of gallbladder polypoid lesions : 15 years of experience. Pol Przegl Chir 2013 ; 85 : 625-629.
13) 小坂俊仁, 乾和郎, 芳野純治, 若林貴夫, 小林隆, 三好広尚, 他. 検診で発見された胆嚢ポリープ切除例の検討. 日消がん検診誌 2012 ; 50 : 529-536.
14) Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol 2013 ; 59 : 571-582.

第IV章. 診断

P.32 掲載の参考文献
1) Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma : a systematic review of the current literature. J Am Coll Surg 2009 ; 208 : 134-147.
2) DeOliveira ML, Cunningham SC, Cameron JL, Kamanger F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma : thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007 ; 245 : 755-762.
3) Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-140.
4) 小林省吾, 永野浩昭, 土岐祐一郎, 森正樹. 肝外胆管 (胆管, 胆嚢管, 総胆管) 腫瘍 肝外胆管系腫瘍 (良性, 悪性). 日本臨床 2011 ; 別冊 (肝・胆道系症候群 III) : 36-40.
5) 広松孝, 長谷川洋, 坂本英至, 小松俊一郎, 田畑智丈, 夏目誠治, 他. 内視鏡下生検が診断に有効であった無黄疸早期胆管癌の1例 : 本邦報告73例の検討. 胆道 2007 ; 21 : 75-81.
6) Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder : results of the French surgical association survey. Ann Surg 1994 ; 219 : 275-280.
7) Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003 ; 4 : 167-176.
8) Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades : a single-institution experience. Arch Surg 2009 ; 144 : 441-447.
9) Tran TB, Norton JA, Ethun CG, Pawlik TM, Buettner S, Schmidt C, et al. Gallbladder cancer presenting with jaundice : uniformly fatal or still potentially curable? J Gastrointest Surg 2017 ; 21 : 1245-1253.
10) Nishio H, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Gallbladder cancer involving the extrahepatic bile duct is worthy of resection. Ann Surg 2011 ; 253 : 953-960.
11) 三好広尚, 乾和郎, 芳野純治, 服部昌志, 若林貴夫, 奥嶋一武, 他. 胆嚢癌の超音波診断の現況と問題点. 肝胆膵 2006 ; 53 : 201-204.
12) Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients : implications for surgical strategy and long-term prognosis. J Gastrointest Surg 2010 ; 14 : 379-387.
14) Kamisawa T, Tu Y, Egawa N, Nakajima H, Horiguchi S, Tsuruta K, et al. Clinicopathologic features of ampullary carcinoma without jaundice. J Clin Gastroenterol 2006 ; 40 : 162-166.
P.34 掲載の参考文献
1) Cha JM, Kim MH, Lee SK, Seo DW, Lee SS, Lee JH, et al. Clinicopathological review of 61 patients with early bile duct cancer. Clin Oncol (R Coll Radiol 2006 ; 18 : 669-677.
2) Stepien M, Fedirko V, Duarte-Salles T, Ferrari P, Freisling H, Trepo E, et al. Prospective association of liver function biomarkers with development of hepatobiliary cancers. Cancer Epidemiol 2016 ; 40 : 179-187.
3) 皆川紀剛, 山口幸二. 膵癌・胆道癌の腫瘍マーカー. 成人病と生活習慣病 2011 ; 41 ; 654-660.
4) Liang B, Zhong L, He Q, Wang S, Pan Z, Wang T, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma : a systematic review and meta-analysis. Med Sci Monit 2015 ; 21 : 3555-3563.
5) Wang YF, Feng FL, Zhao XH, Ye ZX, Zeng HP, Li Z, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol 2014 ; 20 : 4085-4092.
6) Tse F, Barkun JS, Romagnuolo J, Friedman G, Bornstein JD, Barkun AN. Nonoperative imaging techniques in suspected biliary tract obstruction. HPB (Oxford) 2006 ; 8 : 409-425.
7) Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma : a systematic review of the current literature. J Am Coll Surg 2009 ; 208 : 134-147.
8) Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 2006 ; 11 : 913-922.
9) Albu S, Tantau M, Sparchez Z, Branda H, Suteu T, Badea R, et al. Diagnosis and treatment of extrahepatic cholangiocarcinoma : results in a series of 124 patients. Rom J Gastroenterol 2005 ; 14 : 33-36.
10) Inui K, Yoshino J, Miyoshi H. Diagnosis of gallbladder tumors. Intern Med 2011 ; 50 : 1133-1136.
11) Kim JH, Lee JY, Baek JH, Eun HW, Kim YJ, Han JK, et al. High-resolution sonography for distinguishing neoplastic gallbladder polyps and staging gallbladder cancer. AJR Am J Roentgenol 2015 ; 204 : W150-159.
12) Hirooka Y, Naitoh Y, Goto H, Furukawa T, Ito A, Hayakawa T. Differential diagnosis of gall-bladder masses using colour Doppler ultrasonography. J Gastroenterol Hepatol 1996 ; 11 : 840-846.
13) Wang W, Fei Y, Wang F. Meta-analysis of contrast-enhanced ultrasonography for the detection of gallbladder carcinoma. Med Ultrason 2016 ; 18 : 281-228.
14) Chen WX, Xie QG, Zhang WF, Zhang X, Hu TT, Xu P, et al. Multiple imaging techniques in the diagnosis of ampullary carcinoma. Hepatobiliary Pancreat Dis Int 2008 ; 7 : 649-653.
P.36 掲載の参考文献
1) Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma : expert 15 ; 17 : 691-699.
2) Ray CE Jr, Lorenz JM, Burke CT, Darcy MD, Fidelman N, Greene FL, et al. ACR Appropriateness Criteria radiologic management of benign and malignant biliary obstruction. J Am Coll Radiol 2013 ; 10 : 567-574.
3) Ruys AT, van Beem BE, Engelbrecht MR, Bipat S, Stoker J, Van Gulik TM. Radiological staging in patients with hilar cholangiocarcinoma : a systematic review and meta-analysis. Br J Radiol 2012 ; 85 : 1255-1262.
4) Okuda Y, Taura K, Seo S, Yasuchika K, Nitta T, Ogawa K, et al. Usefulness of operative planning based on 3-dimensional CT cholangiography for biliary malignancies. Surgery 2015 ; 158 : 1261-1271.
5) Endo I, Shimada H, Sugita M, Fujii Y, Morioka D, Takeda K, et al. Role of three-dimensional imaging in operative planning for hilar cholangiocarcinoma. Surgery 2007 ; 142 : 666-675.
6) Unno M, Okumoto T, Katayose Y, Rikiyama T, Sato A, Motoi F, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg 2007 ; 14 : 434-440.
7) Senda Y, Nishio H, Oda K, Yokoyama Y, Ebata T, Igami T, et al. Value of multidetector-row CT in the assessment of longitudinal extension of cholangiocarcinoma : correlation between MDCT and microscopic findings. World J Surg 2009 ; 33 : 1459-1467.
8) Sugiura T, Nishio H, Nagino M, Senda Y, Ebata T, Yokoyama Y, et al. Value of multidetector-row computed tomography in diagnosis of portal vein invasion by perihilar cholangiocarcinoma. World J Surg 2008 ; 32 : 1478-1484.
9) Fukami Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Diagnostic ability of MDCT to assess right hepatic artery invasion by perihilar cholangiocarcinoma with left-sided predominance. J Hepatobiliary Pancreat Sci 2012 ; 19 : 179-186.
10) Sun N, Xu Q, Liu X, Liu W, Wang J. Comparison of preoperative evaluation of malignant low-level biliary obstruction using plain magnetic resonance and coronal liver acquisition with volume acceleration technique alone and in combination. Eur J Med Res 2015 ; 20 : 92.
P.39 掲載の参考文献
1) American Society for Gastrointestinal Endoscopy (ASGE) Standards of Practice Committee, Anderson MA, Appalaneni V, Ben-Menachem T, Decker GA, Early DS, Evans JA, et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc 2013 ; 77 : 167-174.
2) Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 2011 ; 46 : 242-248.
3) Kawashima H, Itoh A, Ohno E, Itoh Y, Ebata T, Nagino M, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma : a retrospective study of efficacy and risk factors related to complications. Ann Surg 2013 ; 257 : 121-127.
4) Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures : a systematic review and meta-analysis. Gastrointest Endosc 2015 ; 81 : 168-176.
5) Noda Y, Fujita N, Kobayashi G, Ito K, Horaguchi J, Hashimoto S, et al. Prospective randomized controlled study comparing cell block method and conventional smear method for bile cytology. Dig Endosc 2013 ; 25 : 444-452.
6) Smoczynski M, Jablonska A, Matyskiel A, Lakomy J, Dubowik M, Marek I, et al. Routine brush cytology and fluorescence in situ hybridization for assessment of pancreatobiliary strictures. Gastrointest Endosc 2012 ; 75 : 65-73.
7) Layfield LJ, Ehya H, Filie AC, Hruban RH, Jhala N, Joseph L, et al. Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions : the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology. Diagn Cytopathol 2014 ; 42 : 351-362.
8) Tamada K, Ushio J, Sugano K. Endoscopic diagnosis of extrahepatic bile duct carcinoma : Advances and current limitations. World J Clin Oncol 2011 ; 2 : 203-216.
9) Osanai M, Itoi T, Igarashi Y, Tanaka K, Kida M, Maguchi H, et al. Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension : a prospective multicenter study. Endoscopy 2013 ; 45 : 635-642.
10) Nishikawa T, Tsuyuguchi T, Sakai Y, Sugiyama H, Miyazaki M, Yokosuka O. Comparison of the diagnostic accuracy of peroral video-cholangioscopic visual findings and cholangioscopy-guided forceps biopsy findings for indeterminate biliary lesions : a prospective study. Gastrointest Endosc 2013 ; 77 : 219-226.
11) Manta R, Frazzoni M, Conigliaro R, Maccio L, Melotti G, Dabizzi E, et al. SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions : a single-center, prospective, cohort study. Surg Endosc 2013 ; 27 : 1569-1572.
12) Ramchandani M, Reddy DN, Lakhtakia S, Tandan M, Maydeo A, Chandrashekhar TS, et al. Per oral cholangiopancreatoscopy in pancreatico biliary diseases : expert consensus statements. World J Gastroenterol 2015 ; 21 : 4722-4734.
13) Alper E, Arabul M, Buyrac Z, Baydar B, Ustundag Y, Celik M, et al. The use of radial endosonography findings in the prediction of cholangiocarcinoma in cases with distal bile duct obstructions. Hepatogastroenterology 2013 ; 60 : 678-683.
14) Annunziata S, Caldarella C, Pizzuto DA, Galiandro F, Sadeghi R, Giovanella L, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma : a meta-analysis. Biomed Res Int 2014 : 247693.
15) Cheng MF, Wang HP, Tien YW, Liu KL, Yen RF, Tzen KY, et al. Usefulness of PET/CT for the differentiation and characterization of periampullary lesions. Clin Nucl Med 2013 : 38 : 703-708.
P.40 掲載の参考文献
2) Kalra N, Suri S, Gupta R, Natarajan SK, Khandelwal N, Wig JD, et al. MDCT in the staging of gallbladder carcinoma. AJR Am J Roentgenol 2006 ; 186 : 758-762.
3) Engels JT, Balfe DM, Lee JK. Biliary carcinoma : CT evaluation of extrahepatic spread. Radiology 1989 ; 172 : 35-40.
5) Kim SJ, Lee JM, Lee JY, Choi JY, Kim SH, Han JK, et al. Accuracy of preoperative T-staging of gallbladder carcinoma using MDCT. AJR Am J Roentgenol 2008 ; 190 : 74-80.
6) Yoshimitsu K, Honda H, Shinozaki K, Aibe H, Kuroiwa T, Irie H, et al. Helical CT of the local spread of carcinoma of the gallbladder : evaluation according to the TNM system in patients who underwent surgical resection. AJR Am J Roentgenol 2002 ; 179 : 423-428.
7) Jang JY, Kim SW, Lee SE, Hwang DW, Kim EJ, Lee JY, et al. Differential diagnostic and staging accuracies of high resolution ultrasonography, endoscopic ultrasonography, and multidetector computed tomography for gallbladder polypoid lesions and gallbladder cancer. Ann Surg 2009 ; 250 : 943-949.
8) Schwartz LH, Lefkowitz RA, Panicek DM, Coakley FV, Jarnagin W, Dematteo R, et al. Breath-hold magnetic resonance cholangiopancreatography in the evaluation of malignant pancreaticobiliary obstruction. J Comput Assist Tomogr 2003 ; 27 : 307-314.
9) Kim JH, Kim TK, Eun HW, Kim BS, Lee MG, Kim PN, et al. Preoperative evaluation of gallbladder carcinoma : efficacy of combined use of MR imaging, MR cholangiography, and contrast-enhanced dual-phase three-dimensional MR angiography. J Magn Reson Imaging 2002 ; 16 : 676-684.
10) Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, et al. Liver tumors : comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996 ; 200 : 59-67.
11) Lee NK, Kim S, Kim TU, Kim DU, Seo HI, Jeon TY. Diffusion-weighted MRI for differentiation of benign from malignant lesions in the gallbladder. Clin Radiol 2014 ; 69 : e78-85.
12) Kitazume Y, Taura S, Nakaminato S, Noguchi O, Masaki Y, Kasahara I, et al. Diffusion-weighted magnetic resonance imaging to differentiate malignant from benign gallbladder disorders. Eur J Radiol 2016 ; 85 : 864-873.
13) Haradome H, Ichikawa T, Sou H, Yoshikawa T, Nakamura A, Araki T, et al. The pearl necklace sign : an imaging sign of adenomyomatosis of the gallbladder at MR cholangiopancreatography. Radiology 2003 ; 227 : 80-88.
14) Bang SH, Lee JY, Woo H, Joo I, Lee ES, Han JK, et al. Differentiating between adenomyomatosis and gallbladder cancer : revisiting a comparative study of high-resolution ultrasound, multidetector CT, and MR imaging. Korean J Radiol 2014 ; 15 : 226-234.
15) Takuma K, Kamisawa T, Tabata T, Hara S, Kuruma S, Inaba Y, et al. Importance of early diagnosis of pancreaticobiliary maljunction without biliary dilatation. World J Gastroenterol 2012 ; 18 : 3409-3414.
P.42 掲載の参考文献
1) Azuma T, Yoshikawa T, Araida T, Takasaki K. Differential diagnosis of polypoid lesions of the gallbladder by endoscopic ultrasonography. Am J Surg 2001 ; 181 : 65-70.
2) Cheon YK, Cho WY, Lee TH, Cho YD, Moon JH, Lee JS, et al. Endoscopic ultrasonography does not differentiate neoplastic from non-neoplastic small gallbladder polyps. World J Gastroenterol 2009 ; 15 : 2361-2366.
3) Choi WB, Lee SK, Kim MH, Seo DW, Kim HJ, Kim DI, et al. A new strategy to predict the neoplastic polyps of the gallbladder based on a scoring system using EUS. Gastrointest Endosc 2000 ; 52 : 372-379.
4) Jang JY, Kim SW, Lee SE, Hwang DW, Kim EJ, Lee JY, et al. Differential diagnostic and staging accuracies of high resolution ultrasonography, endoscopic ultrasonography, and multidetector computed tomography for gallbladder polypoid lesions and gallbladder cancer. Ann Surg 2009 ; 250 : 943-949.
5) Choi JH, Seo DW, Choi JH, Park DH, Lee SS, Lee SK, et al. Utility of contrast-enhanced harmonic EUS in the diagnosis of malignant gallbladder polyps (with videos). Gastrointest Endosc 2013 ; 78 : 484-493.
6) Hirooka Y, Naitoh Y, Goto H, Ito A, Hayakawa S, Watanabe Y, et al. Contrast-enhanced endoscopic ultrasonography in gallbladder diseases. Gastrointest Endosc 1998 ; 48 : 406-410.
7) Park CH, Chung MJ, Oh TG, Park JY, Bang S, Park SW, et al. Differential diagnosis between gallbladder adenomas and cholesterol polyps on contrast-enhanced harmonic endoscopic ultrasonography. Surg Endosc 2013 ; 27 : 1414-1421.
8) Ramchandani M, Reddy DN, Gupta R, Lakhtakia S, Tandan M, Darisetty S, et al. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions : a single-center, prospective study. Gastrointest Endosc 2011 ; 74 : 511-519.
9) Tsukada K, Takada T, Miyazaki M, Miyakawa S, Nagino M, Kondo S, et al. Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008 ; 15 : 31-40.
10) Itoi T, Sofuni A, Itokawa F, Kurihara T, Tsuchiya T, Moriyasu F, et al. Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. Gastrointest Endosc 2006 ; 64 : 512-519.
11) Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 2010 ; 45 : 560-566.
12) Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma : a prospective study compared with conventional imaging. Am J Gastroenterol 2008 ; 103 : 1145-1151.
13) Kitajima K, Murakami K, Kanegae K, Tamaki N, Kaneta T, Fukuda H, et al. Clinical impact of whole body FDG-PET for recurrent biliary cancer : a multicenter study. Ann Nucl Med 2009 ; 23 : 709-715.
14) Kumar R, Sharma P, Kumari A, Halanaik D, Malhotra A. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma. Clin Nucl Med 2012 ; 37 : 431-435.
P.45 掲載の参考文献
1) Miyazaki M, Ohtsuka M, Miyakawa S, Nagino M, Yamamoto M, Kokudo N, et al. Classification of biliary tract of Hepato-Biliary-Pancreatic Surgery : 3rd English edition. J Hepatobiliary Pancreat Sci 2015 ; 22 : 181-196.
2) Yamaguchi K, Enjoji M, Kitamura K. Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 1990 ; 36 : 588-592.
3) Menzel J, Poremba C, Dietl KH, Bocker W, Domschke W. Tumors of the papilla of Vater-inadequate diagnostic impact of endoscopic forceps biopsies taken prior to and following sphincterotomy. Ann Oncol 1999 ; 10 : 1227-1231.
4) Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T. Tumor of the ampulla of Vater : experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999 ; 134 : 526-532.
5) Elek G, Gyori S, Toth B, Pap A. Histological evaluation of preoperative biopsies from ampulla Vateri. Pathol Oncol Res 2003 ; 9 : 32-41.
6) Lee HS, Jang JS, Lee S, Yeon MH, Kim KB, Park JG, et al. Diagnostic accuracy of the initial endoscopy for ampullary tumors. Clin Endosc 2015 ; 48 : 239-246.
7) Chen CH, Yang CC, Yeh YH, Chou DA, Nien CK. Reappraisal of endosonography of ampullary tumors : correlation with transabdominal sonography, CT, and MRI. J Clin Ultrasound 2009 ; 37 : 18-25.
8) Artifon EL, Couto D Jr, Sakai P, da Silveira EB. Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc 2009 ; 70 : 290-296.
9) Lee M, Kim MJ, Park MS, Choi JY, Chung YE. Using multi-detector-row CT to diagnose ampullary adenoma or adenocarcinoma in situ. Eur J Radiol 2011 ; 80 : e340-345.
10) Menzel J, Hoepffner N, Sulkowski U, Reimer P, Heinecke A, Poremba C, et al. Polypoid tumors of the major duodenal papilla : preoperative staging with intraductal US, EUS, and CT : a prospective, histopathologically controlled study. Gastrointest Endosc 1999 ; 49 : 349-357.
11) Jang KM, Kim SH, Lee SJ, Park HJ, Choi D, Hwang J. Added value of diffusion-weighted MR imaging in the diagnosis of ampullary carcinoma. Radiology 2013 ; 266 : 491-501.
12) Motosugi U, Ichikawa T, Morisaka H, Sou H, Muhi A, Kimura K, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging : comparison with contrast-enhanced multi-detector row CT. Radiology 2011 ; 260 : 446-453.
13) Scharitzer M, Ba-Ssalamah A, Ringl H, Kolblinger C, Grunberger T, Weber M, et al. Preoperative evaluation of colorectal liver metastases : comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 2013 ; 23 : 2187-2196.
P.47 掲載の参考文献
1) Artifon EL, Couto D Jr, Sakai P, da Silveira EB. Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc 2009 ; 70 : 290-296.
2) Menzel J, Hoepffner N, Sulkowski U, Reimer P, Heinecke A, Poremba C, et al. Polypoid tumors of the major duodenal papilla : preoperative staging with intraductal US, EUS, and CT-A prospective, histopathologically controlled study. Gastrointest Endosc 1999 ; 49 : 349-357.
3) Itoh A, Goto H, Naitoh Y, Hirooka Y, Furukawa T, Hayakawa T. Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 1997 ; 45 : 251-260.
4) Ito K, Fujita N, Noda Y, Kobayashi G, Horaguchi J, Takasawa O, et al. Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US : a prospective and histopathologically controlled study. Gastrointest Endosc 2007 ; 66 : 740-747.
5) Trikudanathan G, Njei B, Attam R, Arain M, Shaukat A. Staging accuracy of ampullary tumors by endoscopic ultrasound : meta-analysis and systematic review. Dig Endosc 2014 ; 26 : 617-626.
6) Okano N, Igarashi Y, Hara S, Takuma K, Kamata I, Kishimoto Y, et al. Endosonographic preoperative evaluation for tumors of the ampulla of Vater using endoscopic ultrasonography and intraductal ultrasonography. Clin Endosc 2014 ; 47 : 174-177.
7) Sperti C, Pasquali C, Fiore V, Bissoli S, Chierichetti F, Liessi G, et al. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms. Am J Surg 2006 ; 191 : 743-748.
8) Cheng MF, Wang HP, Tien YW, Liu KL, Yen RF, Tzen KY, et al. Usefulness of PET/CT for the differentiation and characterization of periampullary lesions. Clin Nucl Med 2013 ; 38 : 703-708.
9) Yamada I, Ajiki T, Ueno K, Sawa H, Otsubo I, Yoshida Y, et al. Feasibility of 18F-fluorodeoxyglucose positron-emission tomography for preoperative evaluation of biliary tract cancer. Anticancer Res 2012 ; 32 : 5105-5110.
10) Burge ME, O'Rourke N, Cavallucci D, Bryant R, Francesconi A, Houston K, et al. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers. HPB (Oxford) 2015 ; 17 : 624-631.
P.49 掲載の参考文献
1) Tsuchiya T, Yokoyama Y, Ebata T, Igami T, Sugawara G, Kato K, et al. Randomized controlled trial on timing and number of sampling for bile aspiration cytology. J Hepatobiliary Pancreat Sci 2014 ; 21 : 433-438.
2) Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures : a systematic review and meta-analysis. Gastrointest Endosc 2015 ; 81 : 168-176.
3) Rosch T, Hofrichter K, Frimberger E, Meining A, Born P, Weigert N, et al. ERCP or EUS for tissue diagnosis of biliary strictures? : a prospective comparative study. Gastrointest Endosc 2004 ; 60 : 390-396.
4) Itoi T, Sofuni A, Itokawa F, Kurihara T, Tsuchiya T, Moriyasu F, et al. Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. Gastrointest Endosc 2006 ; 64 : 512-519.
5) Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, et al. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction : results of a prospective, single-blind, comparative study. Gastrointest Endosc 2014 ; 80 : 97-104.
6) Khashab MA, Fockens P, Al-Haddad MA. Utility of EUS in patients with indeterminate biliary strictures and suspected extrahepatic cholangiocarcinoma. Gastrointest Endosc 2012 ; 76 : 1024-1033.
7) Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) 2011 ; 13 : 356-360.
8) Hijioka S, Mekky MA, Bhatia V, Sawaki A, Mizuno N, Hara K, et al. Can EUS-guided FNA distinguish between gallbladder cancer and xanthogranulomatous cholecystitis? Gastrointest Endosc 2010 ; 72 : 622-627.
9) Jacobson BC, Pitman MB, Brugge WR. EUS-guided FNA for the diagnosis of gallbladder masses. Gastrointest Endosc 2003 ; 57 : 251-254.
10) Varadarajulu S, Eloubeidi MA. Endoscopic ultrasound-guided fine-needle aspiration in the evaluation of gallbladder masses. Endoscopy 2005 ; 37 : 751-754.
11) Jacobson BC, Waxman I, Parmar K, Kauffman JM, Clarke GA, Van Dam J. Endoscopic ultrasound-guided gallbladder bile aspiration in idiopathic pancreatitis carries a significant risk of bile peritonitis. Pancreatology 2002 ; 2 : 26-29.
12) Rana C, Krishnani N, Kumari N. Ultrasound-guided fine needle aspiration cytology of gallbladder lesions : a study of 596 cases. Cytopathology 2016 ; 27 : 398-406.

第V章. 胆道ドレナージ

P.52 掲載の参考文献
1) Pitt HA, Gomes AS, Lois JF, Mann LL, Deutsch LS, Longmire WP Jr. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985 ; 201 : 545-553.
2) Lai EC, Mok FP, Fan ST, Lo CM, Chu KM, Liu CL, et al. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994 ; 81 : 1195-1198.
3) Sewnath ME, Karsten TM, Prins MH, Rauws EJ, Obertop H, Gouma DJ. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg 2002 ; 236 : 17-27.
4) Ferrero A, Lo Tesoriere R, Vigano L, Caggiano L, Sgotto E, Capussotti L. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J Surg 2009 ; 33 : 318-325.
5) Liu F, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma : whether or not? : a systematic review. Dig Dis Sci 2011 ; 56 : 663-672.
6) van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010 ; 362 : 129-137.
7) Moole H, Bechtold M, Puli SR. Efficacy of preoperative biliary drainage in malignant obstructive jaundice : a meta-analysis and systematic review. World J Surg Oncol 2016 ; 14 : 182.
8) Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-140.
9) Iacono C, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection : highlights and drawbacks. Ann Surg 2013 ; 257 : 191-204.
10) Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013 ; 100 : 274-283.
11) Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma : results of an Italian multicenter analysis of 440 patients. Arch Surg 2012 ; 147 : 26-34.
12) Kennedy TJ, Yopp A, Qin Y, Zhao B, Guo P, Liu F, et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009 ; 11 : 445-451.
13) Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, van Klaveren D, Allen PJ, et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma : development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg 2016 ; 223 : 321-331.
14) Scheufele F, Schorn S, Demir IE, Sargut M, Tieftrunk E, Calavrezos L, et al. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head : A meta-analysis of current literature. Surgery 2017 ; 161 : 939-950.
15) Choi YM, Cho EH, Lee KY, Ahn SI, Choi SK, Kim SJ, et al. Effect of preoperative biliary drainage on surgical results after pancreaticoduodenectomy in patients with distal common bile duct cancer : focused on the rate of decrease in serum bilirubin. World J Gastroenterol 2008 ; 14 : 1102-1107.
16) Jagannath P, Dhir V, Shrikhande S, Shah RC, Mullerpatan P, Mohandas KM. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg 2005 ; 92 : 356-361.
17) Garcea G, Chee W, Ong SL, Maddern GJ. Preoperative biliary drainage for distal obstruction : the case against revisited. Pancreas 2010 ; 39 : 119-126.
P.56 掲載の参考文献
1) Miura F, Sano K, Wada K, Shibuya M, Ikeda Y, Takahashi K, et al. Prognostic impact of type of preoperative biliary drainage in patients with distal cholangiocarcinoma. Am J Surg 2017 ; 214 : 256-261.
2) Komaya K, Ebata T, Fukami Y, Sakamoto E, Miyake H, Takara D, et al ; Nagoya Surgical Oncology Group. Percutaneous biliary drainage is oncologically inferior to endoscopic drainage : a propensity score matching analysis in resectable distal cholangiocarcinoma. J Gastroenterol 2016 ; 51 : 608-619.
3) Decker C, Christein JD, Phadmis MA, Wilcox CM, Varadarajulu S. Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer. Surg Endosc 2011 ; 25 : 2364-2367.
4) Cavell LK, Allen PJ, Vinoya C, Eaton AA, Gonen M, Gerdes H, et al. Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy. Am J Gastroenterol 2013 ; 108 : 1168-1173.
5) Haapamaki C, Seppanen H, Udd M, Juuti A, Halttunen J, Kiviluoto T, et al. Preoperative biliary decompression preceding pancreaticoduodenectomy with plastic or self-expandable metallic stent. Scand J Surg 2015 ; 104 : 79-85.
6) Crippa S, Cirocchi R, Partelli S, Petrone MC, Muffatti F, Renzi C, et al. Systemic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectable periampullary or pancreatic head tumors. Eur J Surg Oncol 2016 ; 42 : 1278-1285.
7) Tol JA, van Hooft JE, Timmer R, Kubben FJ, van der Harst E, de Hingh IH, et al. Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut 2016 ; 65 : 1981-1987.
8) Huang X, Liang B, Zhao XQ, Zhang FB, Wang XT, Dong JH. The effects of different preoperative biliary drainage methods on complications following pancreaticoduodenectomy. Medicine (Baltimore) 2015 ; 94 : e723.
9) Lin H, Li S, Liu X. The safety and efficacy of nasobiliary drainage versus biliary stenting in malignant biliary obstruction : a systematic review and meta-analysis. Medicine (Baltimore) 2016 ; 95 : e5253.
10) Seo H, Lee JM, Kim IH, Han JK, Kim SH, Jang JY, et al. Evaluation of the gross type and longitudinal extent of extrahepatic cholangiocarcinomas on contrast-enhanced multidetector row computed tomography. J Comput Assist Tomogr 2009 ; 33 : 376-382.
P.57 掲載の参考文献
1) Wiggers JK, Groot Koerkamp B, Coelen RJ, Doussot A, van Dieren S, Rauws EA, et al. Percutaneous preoperative biliary drainage for resectable perihilar cholangiocarcinoma : no association with survival and no increase in seeding metastases. Ann Surg Oncol 2015 ; 22 Supple 3 : S1156-1163.
2) Walter T, Ho CS, Horgan AM, Warkentin A, Gallinger S, Greig PD, et al. Endoscopic or percutaneous biliary drainage for Klatskin tumors? J Vasc Interv Radiol 2013 ; 24 : 113-121.
3) Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 2011 ; 46 : 242-248.
4) Hameed A, Pang T, Chiou J, Pleass H, Lam V, Hollands M, et al. Percutaneous vs. endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma : a systematic review and meta-analysis. HPB (Oxford) 2016 ; 18 : 400-410.
5) Al Mahjoub A, Menahem B, Fohlen A, Dupont B, Alves A, Launoy G, et al. Preoperative biliary drainage in patients with resectable perihilar cholangiocarcinoma : Is percutaneous transhepatic biliary drainage safer and more effective than endoscopic biliary drainage? A meta-analysis. J Vasc Interv Radiol 2017 ; 28 : 576-582.
6) Takahashi Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 2010 ; 97 : 1860-1866.
7) Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage : a propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 2017 ; 161 : 394-404.
8) Higuchi R, Yazawa T, Uemura S, Izumo W, Chaudhary RJ, Furukawa T, et al. ENBD is associated with decreased tumor dissemination compared to PTBD in perihilar cholangiocarcinoma. J Gastrointest Surg 2017 ; 21 : 1506-1514.
9) Noie T, Sugawara Y, Imamura H, Takayama T, Makuuchi M. Selective versus total drainage for biliary obstruction in the hepatic hilus : an experimental study. Surgery 2001 ; 130 : 74-81.
10) Ishizawa T, Hasegawa K, Sano K, Imamura H, Kokudo N, Makuuchi M. Selective versus total drainage for obstructive jaundice caused by a hepatobiliary malignancy. Am J Surg 2007 ; 193 : 149-154.
11) Unno M, Okumoto T, Katayose Y, Rikiyama T, Sato A, Motoi F, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg 2007 ; 14 : 434-440.
P.59 掲載の参考文献
1) Maguchi H, Takahashi K, Katanuma A, Osanai M, Nakahara K, Matuzaki S, et al. Preoperative biliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2007 ; 14 : 441-446.
2) Kloek JJ, van der Gaag NA, Aziz Y, Rauws EA, van Delden OM, Lameris JS, et al. Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg 2010 ; 14 : 119-125.
3) Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 2011 ; 46 : 242-248.
4) Wiggers JK, Groot Koerkamp B, Coelen RJ, Rauws EA, Schattner MA, Nio CY, et al. Preoperative biliary drainage in perihilar cholangiocarcinoma : identifying patients who require percutaneous drainage after failed endoscopic drainage. Endoscopy 2015 ; 47 : 1124-1131.
5) Ito Y, Nakai Y, Isayama H, Tsujino T, Hamada T, Umefune G, et al. Impact of preoperative biliary drainage on surgical outcomes in periampullary and hilar malignancy : a single-center experience. Surg Laparosc Endosc Percutan Tech 2016 ; 26 : 150-155.
6) Sasahira N, Hamada T, Togawa O, Yamamoto R, Iwai T, Tamada K, et al. Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction. World J Gastroenterol 2016 ; 22 : 3793-3802.
7) Kanai M, Nimura Y, Kamiya J, Kondo S, Nagino M, Miyachi M, et al. Preoperative intrahepatic segmental cholangitis in patients with advanced carcinoma involving the hepatic hilus. Surgery 1996 ; 119 : 498-504.
8) Sakata J, Shirai Y, Tsuchiya Y, Wakai T, Nomura T, Hatakeyama K. Preoperative cholangitis independently increases in-hospital mortality after combined major hepatic and bile duct resection for hilar cholangiocarcinoma. Langenbecks Arch Surg 2009 ; 394 : 1065-1072.
9) Jagannath P, Dhir V, Shrikhande S, Shah RC, Mullerpatan P, Mohandas KM. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg 2005 ; 92 : 356-361.
10) Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, van Klaveren D, Allen PJ, et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma : development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg 2016 ; 223 : 321-331.
11) Ribero D, Zimmitti G, Aloia TA, Shindoh J, Fabio F, Amisano M, et al. Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. J Am Coll Surg 2016 ; 223 : 87-97.
P.61 掲載の参考文献
1) 滋野 俊. 内視鏡的逆行性胆管ドレナージ法 (ERBD) と胆汁細菌, 第1編 : ERBD施行例における胆汁中細菌の検討. Gastroenterol Endosc 1990 ; 32 : 334-344.
2) Sakata J, Shirai Y, Tsuchiya Y, Wakai T, Nomura T, Hatakeyama K. Preoperative cholangitis independently increases in-hospital mortality after combined major hepatic and bile duct resection for hilar cholangiocarcinoma. Langenbecks Arch Surg 2009 ; 394 : 1065-1072.
3) Povoski SP, Karpeh MS Jr, Conlon KC, Blumgart LH, Brennan MF. Preoperative biliary drainage : impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy. J Gastrointest Surg 1999 ; 3 : 496-505.
5) Sugawara G, Ebata T, Yokoyama Y, Igami T, Takahashi Y, Takara D, et al. The effect of preoperative biliary drainage on infectious complications after hepatobiliary resection with cholangiojejunostomy. Surgery 2013 ; 153 : 200-210.
6) 坂本和彦, 岡田敏正, 為佐卓夫, 岡正朗. 障害肝を背景とする肝切除例における周術期細菌培養. 日外感染症会誌 2006 ; 3 : 83-86.
7) 藤井義郎, 遠藤格, 増成秀樹, 齋藤修治, 神谷紀之, 永野靖彦, ほか. 胆汁培養からみた悪性胆道疾患の術後抗菌薬投与法について. 胆道 2001 ; 15 : 375-380.
8) Hochwald SN, Burke EC, Jarnagin WR, Fong Y, Blumgart LH. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999 ; 134 : 261-266.
9) Takara D, Sugawara G, Ebata T, Yokoyama Y, Igami T, Nagino M. Preoperative biliary MRSA infection in patients undergoing hepatobiliary resection with cholangiojejunostomy : incidence, antibiotic treatment, and surgical outcome. World J Surg 2011 ; 35 : 850-857.
10) Sugawara G, Yokoyama Y, Ebata T, Igami T, Yamaguchi J, Mizuno T, et al. Preoperative biliary colonization/infection caused by multidrug-resistant (MDR) pathogens in patients undergoing major hepatectomy with extrahepatic bile duct resection. Surgery 2018 ; 163 : 1106-1113.
11) Kusachi S, Kashimura N, Konishi T, Shimizu J, Kusunoki M, Oka M, et al. Length of stay and cost for surgical site infection after abdominal and cardiac surgery in Japanese hospitals : multi-center surveillance. Surg Infect (Larchmt) 2012 ; 13 : 257-265.
12) Okamura K, Tanaka K, Miura T, Nakanishi Y, Noji T, Nakamura T, et al. Randomized controlled trial of perioperative antimicrobial therapy based on the results of preoperative bile cultures in patients undergoing biliary reconstruction. J Hepatobiliary Pancreat Sci 2017 ; 24 : 382-393.
13) Sugawara G, Yokoyama Y, Ebata T, Mizuno T, Yagi T, Ando M, et al. Duration of antimicrobial prophylaxis in patients undergoing major hepatectomy with extrahepatic bile duct resection : A randomized controlled trial. Ann Surg 2018 ; 267 : 142-148.
P.64 掲載の参考文献
1) Kanai M, Tanaka M, Nimura Y, Nagino M, Katoh T, Ozawa T. Mitochondrial dysfunction in the non-obstructed lobe of rat liver after selective biliary obstruction. Hepatogastroenterology 1992 ; 39 : 385-391.
2) Suzuki H, Iyomasa S, Nimura Y, Yoshida S. Internal biliary drainage, unlike external drainage, does not suppress the regeneration of cholestatic rat liver after partial hepatectomy. Hepatology 1994 ; 20 : 1318-1322.
3) Parks RW, Clements WD, Smye MG, Pope C, Rowlands BJ, Diamond T. Intestinal barrier dysfunction in clinical and experimental obstructive jaundice and its reversal by internal biliary drainage. Br J Surg 1996 ; 83 : 1345-1349.
4) Welsh FK, Ramsden CW, MacLennan K, Sheridan MB, Barclay GR, Guillou PJ, et al. Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg 1998 ; 227 : 205-212.
5) Kamiya S, Nagino M, Kanazawa H, Komatsu S, Mayumi T, Takagi K, et al. The value of bile replacement during external biliary drainage : an analysis of intestinal permeability, integrity, and microflora. Ann Surg 2004 ; 239 : 510-517.
6) Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery : a randomized controlled trial. Ann Surg 2006 ; 244 : 706-714.
P.66 掲載の参考文献
1) Smith AC, Dowset JF, Rassell RCG, Hatfield ARW, Cotton PB. Randomized trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 1994 ; 344 : 1655-1660.
2) Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomized trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992 ; 340 : 1488-1492.
3) Lammer J, Hausegger KA, Fluckiger F, Winkelbauer FW, Wildling R, Klein GE, et al. Common bile duct obstruction due to malignancy : treatment with plastic versus metal stents. Radiology 1996 ; 201 : 167-172.
4) Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis : a prospective, randomized, controlled trial. Gastrointest Endosc 2006 ; 63 : 986-995.
5) Isayama H, Yasuda I, Ryozawa S, Maguchi H, Igarashi Y, Matsuyama Y, et al. Results of a Japanese multicenter, randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-TEST) : Covered Wallstent versus DoubleLayer stent. Dig Endosc 2011 ; 23 : 310-315.
6) Almadi MA, Barkun A, Martel M. Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction : a series of meta-analyses. Am J Gastroenterol 2017 ; 112 : 260-273.
7) Isayama H, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N, et al. A prospective randomized study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 2004 ; 53 : 729-734.
8) Krokidis M, Fanelli F, Orgera G, Tsetis D, Mouzas I, Bezzi M, et al. Percutaneous palliation of pancreatic head cancer : randomized comparison of ePTFE/FEP-covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol 2011 ; 34 : 352-361.
9) Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma : covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol 2010 ; 33 : 97-106.
10) Telford JJ, Carr-Locke DL, Baron TH, Poneros JM, Bounds BC, Kelsey PB, et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc 2010 ; 72 : 907-914.
11) Kullman E, Frozanpor F, Soderlund C, Linder S, Sandstrom P, Lindhoff-Larsson A, et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction : results from a randomized, multicenter study. Gastrointest Endosc 2010 ; 72 : 915-923.
12) Saleem A, Leggett CL, Murad MH, Baron TH. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc 2011 ; 74 : 321-327.
13) Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction : a meta-analysis. Clin Gastroenterol Hepatol 2013 ; 11 : 27-37.
14) Hamada T, Nakai Y, Isayama H. Two meta-analyses with different conclusions : stent outcomes should be standardized before their integration. Clin Gastroenterol Hepatol 2013 ; 11 : 748.
15) Isayama H, Hamada T, Yasuda I, Itoi T, Ryozawa S, Nakai Y, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015 ; 27 : 259-264.
P.69 掲載の参考文献
1) Isayama H, Hamada T, Yasuda I, Itoi T, Ryozawa S, Nakai Y, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015 ; 27 : 259-264.
2) Wagner HJ, Knyrim K, Vakil N, Klose KJ. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy 1993 ; 25 : 213-218.
3) Sangchan A, Kongkasame W, Pugkhem A, Jenwitheesuk K, Mairiang P. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma : a randomized controlled trial. Gastrointest Endosc 2012 ; 76 : 93-99.
4) Mukai T, Yasuda I, Nakashima M, Doi S, Iwashita T, Iwata K, et al. Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures : a randomized controlled trial. J Hepatobiliary Pancreat Sci 2013 ; 20 : 214-222.
5) Kaneko T, Sugimori K, Shimizu Y, Miwa H, Kameta E, Koh R, et al. Efficacy of plastic stent placement inside bile ducts for the treatment of unresectable malignant hilar obstruction (with videos). J Hepatobiliary Pancreat Sci 2014 ; 21 : 349-355.
6) Ishiwatari H, Hayashi T, Ono M, Sato T, Kato J. Newly designed plastic stent for endoscopic placement above the sphincter of Oddi in patients with malignant hilar biliary obstruction. Dig Endosc 2013 ; 25 Suppl 2 : 94-99.
7) Inoue T, Okumura F, Naitoh I, Fukusada S, Kachi K, Ozeki T, et al. Feasibility of the placement of a novel 6-mm diameter threaded fully covered self-expandable metal stent for malignant hilar biliary obstructions (with videos). Gastrointest Endosc 2016 ; 84 : 352-357.
8) Yoshida T, Hara K, Imaoka H, Hijioka S, Mizuno N, Ishihara M, et al. Benefits of side-by-side deployment of 6-mm covered self-expandable metal stents for hilar malignant biliary obstructions. J Hepatobiliary Pancreat Sci 2016 ; 23 : 548-555.
9) De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C. Unilateral vs bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction : results of a prospective, randomized and controlled study. Gastrointest Endosc 2001 ; 53 : 547-553.
10) Vienne A, Hobeika E, Gouya H, Lapidus N, Fritsch J, Choury AD, et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures : the role of liver volume assessment. Gastrointest Endosc 2010 ; 72 : 728-735.
11) Takahashi E, Fukasawa M, Sato T, Takano S, Kadokura M, Shindo H, et al. Biliary drainage strategy of unresectable malignant hilar strictures by computed tomography volumetry. World J Gastroenterol 2015 ; 21 : 4946-4953.
12) Lee TH, Kim TH, Moon JH, Lee SH, Choi HJ, Hwangbo Y, et al. Bilateral versus unilateral placement of metal stents for inoperable high-grade malignant hilar biliary strictures : a multicenter, prospective, randomized study (with video). Gastrointest Endosc 2017 ; 86 : 817-827.
13) Kogure H, Isayama H, Nakai Y, Tsujino T, Ito Y, Yamamoto K, et al. Newly designed large cell Niti-S stent for malignant hilar biliary obstruction : a pilot study. Surg Endosc 2011 ; 25 : 463-467.
14) Chennat J, Waxman I. Initial performance profile of a new 6F self-expanding metal stent for palliation of malignant hilar biliary obstruction. Gastrointest Endosc 2010 ; 72 : 632-636.

第VI章. 外科治療

P.72 掲載の参考文献
1) Yokoyama Y, Nishio H, Ebata T, Igami T, Sugawara G, Nagino M. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 2010 ; 97 : 1260-1268.
2) Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection : methodology and clinical associations. Surgery 2000 ; 127 : 512-519.
3) Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003 ; 237 : 686-693.
4) Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001 ; 234 : 507-517.
5) Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, et al. Gallbladder cancer (GBC) : 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 2008 ; 98 : 485-489.
7) Hemming AW, Reed AI, Langham MR Jr, Fujita S, Howard RJ. Combined resection of the liver and inferior vena cava for hepatic malignancy. Ann Surg 2004 ; 239 : 712-719.
8) Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma : rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008 ; 248 : 84-96.
9) Konstantinidis IT, Groot Koerkamp B, Do RK, Gonen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma : Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016 ; 122 : 758-765.
10) Croome KP, Rosen CB, Heimbach JK, Nagorney DM. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma? J Am Coll Surg 2015 ; 221 : 130-139.
11) Tan JW, Hu BS, Chu YJ, Tan YC, Ji X, Chen K, et al. One-stage resection for Bismuth type IV hilar cholangiocarcinoma with high hilar resection and parenchyma-preserving strategies : a cohort study. World J Surg 2013 ; 37 : 614-621.
12) Matsuo K, Rocha FG, Ito K, D'Angelica MI, Allen PJ, Fong Y, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma : analysis of resectability and outcomes in 380 patients. J Am Coll Surg 2012 ; 215 : 343-355.
13) Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999 ; 230 : 808-818.
14) Shimizu H, Kimura F, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance : radicality and safety of left-sided hepatectomy. Ann Surg 2010 ; 251 : 281-286.
15) Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma : an audit of 50 consecutive cases. Ann Surg 2010 ; 252 : 115-123.
16) Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma : does it work or not? Surgery 2007 ; 141 : 581-588.
17) Kwon W, Jang JY, Chang YR, Jung W, Kang MJ, Kim SW. Suggestions for improving perihilar cholangiocarcinoma staging based on an evaluation of the seventh edition AJCC system. J Gastrointest Surg 2015 ; 19 : 666-674.
18) Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma : expert consensus statement. HPB (Oxford) 2015 ; 17 : 691-699.
19) Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford) 2013 ; 15 : 492-503.
20) Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document : cholangiocarcinoma : current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016 ; 13 : 261-280.
21) Shimada H, Endo I, Sugita M, Masunari H, Fujii Y, Tanaka K, et al. Hepatic resection combined with portal vein or hepatic artery reconstruction for advanced carcinoma of the hilar bile duct and gallbladder. World J Surg 2003 ; 27 : 1137-1142.
22) Kobayashi A, Oda T, Fukunaga K, Sasaki R, Ohkohchi N. Invasion of the hepatic artery is a crucial predictor of poor outcomes in gallbladder carcinoma. World J Surg 2012 ; 36 : 645-650.
23) Higuchi R, Ota T, Araida T, Kajiyama H, Yazawa T, Furukawa T, et al. Surgical approaches to advanced gallbladder cancer : a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol 2014 ; 21 : 4308-4316.
24) Yamamoto Y, Sugiura T, Ashida R, Okamura Y, Ito T, Uesaka K. Indications for major hepatectomy and combined procedures for advanced gallbladder cancer. Br J Surg 2017 ; 104 : 257-266.
25) Nishio H, Nagino M, Ebata T, Yokoyama Y, Igami T, Nimura Y. Aggressive surgery for stage IV gallbladder carcinoma ; what are the contraindications? J Hepatobiliary Pancreat Surg 2007 ; 14 : 351-357.
26) Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer : a retrospective single-center study. Ann Surg Oncol 2013 ; 20 : 318-324.
27) Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012 ; 143 : 88-98.
28) Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma : a systematic review. HPB (Oxford) 2014 ; 16 : 297-303.
P.76 掲載の参考文献
1) Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma : a preliminary report. Surgery 1990 ; 107 : 521-527.
3) Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nagino M. Portal vein embolization before extended hepatectomy for biliary cancer : current technique and review of 494 consecutive embolizations. Dig Surg 2012 ; 29 : 23-29.
4) Geisel D, Raabe P, Ludemann L, Malinowski M, Stockmann M, Seehofer D, et al. Gd-EOB-DTPA-enhanced MRI for monitoring future liver remnant function after portal vein embolization and extended hemihepatectomy : A prospective trial. Eur Radiol 2017 ; 27 : 3080-3087.
5) Yamashita S, Sakamoto Y, Yamamoto S, Takemura N, Omichi K, Shinkawa H, et al. Efficacy of preoperative portal vein embolization among patients with hepatocellular carcinoma, biliary tract cancer, and colorectal liver metastases : a comparative study based on single-center experience of 319 cases. Ann Surg Oncol 2017 ; 24 : 1557-1568.
6) Komori K, Nagino M, Nimura Y. Hepatocyte morphology and kinetics after portal vein embolization. Br J Surg 2006 ; 93 : 745-751.
7) Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s : an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000 ; 191 : 38-46.
8) Kenjo A, Miyata H, Gotoh M, Kitagawa Y, Shimada M, Baba H, et al. Risk stratification of 7,732 hepatectomy cases in 2011 from the National Clinical Database for Japan. J Am Coll Surg 2014 ; 218 : 412-422.
9) Yigitler C, Farges O, Kianmanesh R, Regimbeau JM, Abdalla EK, Belghiti J. The small remnant liver after major liver resection : how common and how relevant? Liver Transpl 2003 ; 9 : S18-25.
10) Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002 ; 137 : 675-680.
11) Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, et al. Three hundred and one consecutive extended right hepatectomies : evaluation of outcome based on systematic liver volumetry. Ann Surg 2009 ; 250 : 540-548.
12) Madoff DC, Gaba RC, Weber CN, Clark TW, Saad WE. Portal venous interventions : state of the art. Radiology 2016 ; 278 : 333-353.
13) Kang MJ, Jang JY, Kwon W, Park JW, Chang YR, Kim SW. Does preoperative portal vein embolization have any impact on the outcome of right-side hepatectomy for Klatskin tumor? J Gastrointest Surg 2013 ; 17 : 1592-1599.
14) Olthof PB, Wiggers JK, Groot Koerkamp B, Coelen RJ, Allen PJ, Besselink MG, et al. Postoperative liver failure risk score : identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization. J Am Coll Surg 2017 ; 225 : 387-394.
15) Higuchi R, Yamamoto M. Indications for portal vein embolization in perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014 ; 21 : 542-549.
16) Narula N, Aloia TA. Portal vein embolization in extended liver resection. Langenbecks Arch Surg 2017 ; 402 : 727-735.
17) Lee EC, Park SJ, Han SS, Park HM, Lee SD, Kim SH, et al. Mortality after portal vein embolization : Two case reports. Medicine (Baltimore) 2017 ; 96 : e5446.
18) Mohammed M, Kobayashi K, Jawed M. Biliary-pleural fistula following portal vein embolization for perihilar cholangiocarcinoma. Case Rep Gastroenterol 2017 ; 11 : 277-283.
19) Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-140.
P.79 掲載の参考文献
1) Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007 ; 356 : 1545-1559.
2) Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, Yamaguchi J, et al. The Predictive value of indocyanine green clearance in future liver remnant for posthepatectomy liver failure following hepatectomy with extrahepatic bile duct resection. World J Surg 2016 ; 40 : 1440-1447.
3) Yokoyama Y, Nishio H, Ebata T, Igami T, Sugawara G, Nagino M. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 2010 ; 97 : 1260-1268.
4) Kenjo A, Miyata H, Gotoh M, Kitagawa Y, Shimada M, Baba H, et al. Risk stratification of 7, 732 hepatectomy cases in 2011 from the National Clinical Database for Japan. J Am Coll Surg 2014 ; 218 : 412-422.
5) Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-140.
6) Ribero D, Zimmitti G, Aloia TA, Shindoh J, Fabio F, Amisano M, et al. Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. J Am Coll Surg 2016 ; 223 : 87-97.
7) Olthof PB, Wiggers JK, Groot Koerkamp B, Coelen RJ, Allen PJ, Besselink MG, et al. Postoperative liver failure risk score : identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization. J Am Coll Surg 2017 ; 225 : 387-394.
8) Geisel D, Raabe P, Ludemann L, Malinowski M, Stockmann M, Seehofer D, et al. Gd-EOB-DTPA-enhanced MRI for monitoring future liver remnant function after portal vein embolization and extended hemihepatectomy : a prospective trial. Eur Radiol 2017 ; 27 : 3080-3087.
9) Sumiyoshi T, Shima Y, Okabayashi T, Noda Y, Hata Y, Murata Y, et al. Functional discrepancy between two liver lobes after hemilobe biliary drainage in patients with jaundice and bile duct cancer : an appraisal using 99mTc-GSA SPECT/CT fusion imaging. Radiology 2014 ; 273 : 444-451.
10) Sumiyoshi T, Shima Y, Okabayashi T, Kozuki A, Hata Y, Noda Y, et al. Liver function assessment using 99mTc-GSA single-photon emission computed tomography (SPECT)/CT fusion imaging in hilar bile duct cancer : a retrospective study. Surgery 2016 ; 160 : 118-126.
P.82 掲載の参考文献
2) Igami T, Nishio H, Ebata T, Yokoyama Y, Sugawara G, Nimura Y, et al. Surgical treatment of hilar cholangiocarcinoma in the "new era" : the Nagoya University experience. J Hepatobiliary Pancreat Sci 2010 ; 17 : 449-454.
3) Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma : does it work or not? Surgery 2007 ; 141 : 581-588.
4) Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, et al. Surgical treatment of hilar cholangiocarcinoma in the new era : the Asan experience. J Hepatobiliary Pancreat Sci 2010 ; 17 : 476-489.
5) Hemming AW, Mekeel K, Khanna A, Baquerizo A, Kim RD. Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg 2011 ; 212 : 604-613.
6) de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma : a multi-institutional analysis of 305 cases. Cancer 2012 ; 118 : 4737-4747.
7) Wang ST, Shen SL, Peng BG, Hua YP, Chen B, Kuang M, et al. Combined vascular resection and analysis of prognostic factors for hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2015 ; 14 : 626-632.
8) Nakanishi Y, Tsuchikawa T, Okamura K, Nakamura T, Tamoto E, Murakami S, et al. Prognostic impact of the site of portal vein invasion in patients with surgically resected perihilar cholangiocarcinoma. Surgery 2016 ; 159 : 1511-1519.
9) Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K. No-touch resection of hilar malignancies with right hepatectomy and routine portal reconstruction. J Hepatobiliary Pancreat Surg 2009 ; 16 : 502-507.
10) Tamoto E, Hirano S, Tsuchikawa T, Tanaka E, Miyamoto M, Matsumoto J, et al. Portal vein resection using the no-touch technique with a hepatectomy for hilar cholangiocarcinoma. HPB (Oxford) 2014 ; 16 : 56-61.
11) Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W, et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 2012 ; 19 : 1602-1608.
12) Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford) 2013 ; 15 : 492-503.
13) Chen W, Ke K, Chen YL. Combined portal vein resection in the treatment of hilar cholangiocarcinoma : a systematic review and meta-analysis. Eur J Surg Oncol 2014 ; 40 : 489-495.
14) Kurosaki I, Hatakeyama K, Minagawa M, Sato D. Portal vein resection in surgery for cancer of biliary tract and pancreas : special reference to the relationship between surgical outcome and site of primary tumor. J Gastrointest Surg 2008 ; 12 : 907-918.
15) Miura F, Sano K, Amano H, Toyota N, Wada K, Yoshida M, et al. Evaluation of portal vein invasion of distal cholangiocarcinoma as borderline resectability. J Hepatobiliary Pancreat Sci 2015 ; 22 : 294-300.
16) Maeta T, Ebata T, Hayashi E, Kawahara T, Mizuno S, Matsumoto N, et al. Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. Br J Surg 2017 ; 104 : 1549-1557.
18) Nishio H, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Gallbladder cancer involving the extrahepatic bile duct is worthy of resection. Ann Surg 2011 ; 253 : 953-960.
19) Yamamoto Y, Sugiura T, Ashida R, Okamura Y, Ito T, Uesaka K. Indications for major hepatectomy and combined procedures for advanced gallbladder cancer. Br J Surg 2007 ; 104 : 257-266.
20) Yamanaka N, Yasui C, Yamanaka J, Ando T, Kuroda N, Maeda S, et al. Left hemihepatectomy with microsurgical reconstruction of the right-sided hepatic vasculature : a strategy for preserving hepatic function in patients with proximal bile duct cancer. Langenbecks Arch Surg 2001 ; 386 : 364-368.
21) Sakamoto Y, Sano T, Shimada K, Kosuge T, Kimata Y, Sakuraba M, et al. Clinical significance of reconstruction of the right hepatic artery for biliary malignancy. Langenbecks Arch Surg 2006 ; 391 : 203-208.
22) Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma. an audit of 50 consecutive cases. Ann Surg 2010 ; 252 : 115-123.
23) Noji T, Tsuchikawa T, Okamura K, Nakamura T, Tamoto E, Shichinohe T, et al. Resection and reconstruction of the hepatic artery for advanced perihilar cholangiocarcinoma : result of arterioportal shunting. J Gastrointest Surg 2015 ; 19 : 675-681.
P.85 掲載の参考文献
1) Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma : a single-center review of 85 consecutive patients. Ann Surg 2012 ; 256 : 297-305.
2) Aoki T, Sakamoto Y, Kohno Y, Akamatsu N, Kaneko J, Sugawara Y, et al. Hepatopancreaticoduodenectomy for biliary cancer : strategies for near-zero operative mortality and acceptable long-term outcome. Ann Surg 2018 ; 267 : 332-337.
3) Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Onoe S. Major hepatopancreatoduodenectomy with simultaneous resection of the hepatic artery for advanced biliary cancer. Langenbecks Arch Surg 2016 ; 401 : 471-478.
4) Kaneoka Y, Yamaguchi A, Isogai M, Kumada T. Survival benefit of hepatopancreatoduodenectomy for cholangiocarcinoma in comparison to hepatectomy or pancreatoduodenectomy. World J Surg 2010 ; 34 : 2662-2670.
5) Miwa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, Kusama K, et al. Is major hepatectomy with pancreatoduodenectomy justified for advanced biliary malignancy? J Hepatobiliary Pancreat Surg 2007 ; 14 : 136-141.
6) Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma : Long-term results. World J Surg 2008 ; 32 : 1067-1074.
7) Lim CS, Jang JY, Lee SE, Kang MJ, Kim SW. Reappraisal of hepatopancreatoduodenectomy as a treatment modality for bile duct and gallbladder cancer. J Gastrointest Surg 2012 ; 16 : 1012-1018.
8) Sakamoto Y, Nara S, Kishi Y, Esaki M, Shimada K, Kokudo N, et al. Is extended hemihepatectomy plus pancreaticoduodenectomy justified for advanced bile duct cancer and gallbladder cancer? Surgery 2013 ; 153 : 794-800.
9) Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Uemura S, et al. Is combined pancreatoduodenectomy for advanced gallbladder cancer justified? Surgery 2016 ; 159 : 810-820.
10) Kaneoka Y, Yamaguchi A, Isogai M. Hepatopancreatoduodenectomy : its suitability for bile duct cancer versus gallbladder cancer. J Hepatobiliary Pancreat Surg 2007 ; 14 : 142-148.
11) Ebata T, Nagino M, Nishio H, Arai T, Nimura Y. Right hepatopancreatoduodenectomy : improvements over 23 years to attain acceptability. J Hepatobiliary Pancreat Surg 2007 ; 14 : 131-135.
P.87 掲載の参考文献
1) 日本内視鏡外科学会. 内視鏡外科手術に関するアンケート調査 第13回集計結果報告. 日内視鏡外会誌 2016 ; 21 : 655-804.
2) Goetze TO, Paolucci V. Prognosis of incidental gallbladder carcinoma is not influenced by the primary access technique : analysis of 837 incidental gallbladder carcinomas in the German Registry. Surg Endosc 2013 ; 27 : 2821-2828.
4) Sarli L, Pietra N, Costi R, Grattarola M. Gallbladder perforation during laparoscopic cholecystectomy. World J Surg 1999 ; 23 : 1186-1190.
5) De Simone P, Donadio R, Urbano D. The risk of gallbladder perforation at laparoscopic cholecystectomy. Surg Endosc 1999 ; 13 : 1099-1102.
6) Ouchi K, Mikuni J, Kakugawa Y ; Organizing Committee, The 30th Annual Congress of the Japanese Society of Biliry Surgery. Laparoscopic cholecystectomy for gallbladder carcinoma : results of a Japanese survey of 498 patients. J Hepatobiliary Pancreat Surg 2002 ; 9 : 256-260.
7) Lee JM, Kim BW, Kim WH, Wang HJ, Kim MW. Clinical implication of bile spillage in patients undergoing laparoscopic cholecystectomy for gallbladder cancer. Am Surg 2011 ; 77 : 697-701.
8) Steinert R, Nestler G, Sagynaliev E, Muller J, Lippert H, Reymond MA. Laparoscopic cholecystectomy and gallbladder cancer. J Surg Oncol 2006 ; 93 : 682-689.
9) Wakai T, Shirai Y, Hatakeyama K. Radical second resection provides survival benefit for patients with T2 gallbladder carcinoma first discovered after laparoscopic cholecystectomy. World J Surg 2002 ; 26 : 867-871.
10) Paolucci V, Schaeff B, Schneider M, Gutt C. Tumor seeding following laparoscopy : international survey. World J Surg 1999 ; 23 : 989-995.
12) Z'Graggen K, Birrer S, Maurer CA, Wehrli H, Klaiber C, Baer HU. Incidence of port site recurrence after laparoscopic cholecystectomy for preoperatively unsuspected gallbladder carcinoma. Surgery 1998 ; 124 : 831-838.
13) Itano O, Oshima G, Minagawa T, Shinoda M, Kitago M, Abe Y, et al. Novel strategy for laparoscopic treatment of pT2 gallbladder carcinoma. Surg Endosc 2015 ; 29 : 3600-3607.
14) Yoon YS, Han HS, Cho JY, Choi Y, Lee W, Jang JY, et al. Is Laparoscopy contraindicated for gallbladder cancer? : a 10-year prospective cohort study. J Am Coll Surg 2015 ; 221 : 847-853.
15) Agarwal AK, Javed A, Kalayarasan R, Sakhuja P. Minimally invasive versus the conventional open surgical approach of a radical cholecystectomy for gallbladder cancer : a retrospective comparative study. HPB (Oxford) 2015 ; 17 : 536-541.
16) Shirobe T, Maruyama S. Laparoscopic radical cholecystectomy with lymph node dissection for gallbladder carcinoma. Surg Endosc 2015 ; 29 : 2244-2250.
17) Jang JY, Heo JS, Han Y, Chang J, Kim JR, Kim H, et al. Impact of type of surgery on survival outcome in patients with early gallbladder cancer in the era of minimally invasive surgery : oncologic safety of laparoscopic surgery. Medicine (Baltimore) 2016 ; 95 : e3675.
18) 本田五郎, 倉田昌直, 奥田雄紀浩, 小林信, 坂元克考, 堀口慎一郎, 他. 早期胆嚢癌に対する腹腔鏡下胆嚢全層切除のコツとその剥離層の組織学的検討. 胆道 2013 ; 27 : 705-711.
19) Ha TY, Yoon YI, Hwang S, Park YJ, Kang SH, Jung BH, et al. Effect of reoperation on long-term outcome of pT1b/T2 gallbladder carcinoma after initial laparoscopic cholecystectomy. J Gastrointest Surg 2015 ; 19 : 298-305.
P.88 掲載の参考文献
1) Tsukada K, Hatakeyama K, Kurosaki I, Uchida K, Shirai Y, Muto T, et al. Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. Surgery 1996 ; 120 : 816-821.
2) Shimizu Y, Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, et al. Should the extrahepatic bile duct be resected for locally advanced gallbladder cancer? Surgery 2004 ; 136 : 1012-1017.
3) Wakai T, Shirai Y, Sakata J, Tsuchiya Y, Nomura T, Hatakeyama K. Surgical outcomes of minor hepatectomy for locally advanced gallbladder carcinoma. Hepatogastroenterology 2012 ; 59 : 2083-2088.
4) Horiguchi A, Miyakawa S, Ishihara S, Miyazaki M, Ohtsuka M, Shimizu H, et al. Gallbladder bed resection or hepatectomy of segments 4a and 5 for pT2 gallbladder carcinoma : analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 518-524.
5) Choi SB, Han HJ, Kim WB, Song TJ, Suh SO, Choi SY. Surgical strategy for T2 and T3 gallbladder cancer : is extrahepatic bile duct resection always necessary? Langenbecks Arch Surg 2013 ; 398 : 1137-1144.
6) Higuchi R, Ota T, Araida T, Kajiyama H, Yazawa T, Furukawa T, et al. Surgical approaches to advanced gallbladder cancer : a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol 2014 ; 21 : 4308-4016.
7) Ha TY, Yoon YI, Hwang S, Park YJ, Kang SH, Jung BH, et al. Effect of reoperation on long-term outcome of pT1b/T2 gallbladder carcinoma after initial laparoscopic cholecystectomy. J Gastrointest Surg 2015 ; 19 : 298-305.
8) Igami T, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, et al. Combined extrahepatic bile duct resection for locally advanced gallbladder carcinoma : does it work? World J Surg 2015 ; 39 : 1810-1817.
11) Sakamoto Y, Kosuge T, Shimada K, Sano T, Hibi T, Yamamoto J, et al. Clinical significance of extrahepatic bile duct resection for advanced gallbladder cancer. J Surg Oncol 2006 ; 94 : 298-306.
12) Ishizuka D, Shirai Y, Hatakeyama K. Ischemic biliary stricture due to lymph node dissection in the hepatoduodenal ligament. Hepatogastroenterology 1998 ; 45 : 2048-2050.
P.91 掲載の参考文献
1) 佐藤智丈. ヒト肝鋳型標本よりみた胆嚢静脈の解剖学的研究. 胆道 1989 ; 3 : 227-233.
2) Yoshimitsu K, Honda H, Kaneko K, Kuroiwa T, Irie H, Chijiiwa K, et al. Anatomy and clinical importance of cholecystic venous drainage : helical CT observations during injection of contrast medium into the cholecystic artery. AJR Am J Roentgenol 1997 ; 169 : 505-510.
3) Sugita M, Ryu M, Satake M, Kinoshita T, Konishi M, Inoue K, et al. Intrahepatic inflow areas of the drainage vein of the gallbladder : analysis by angio-CT. Surgery 2000 ; 128 : 417-421.
4) Endo I, Shimada H, Takimoto A, Fujii Y, Miura Y, Sugita M, et al. Microscopic liver metastasis : prognostic factor for patients with pT2 gallbladder carcinoma. World J Surg 2004 ; 28 : 692-696.
5) Fahim RB, McDonald JR, Richards JC, Ferris DO. Carcinoma of the gallbladder : a study of its modes of spread. Ann Surg 1962 ; 156 : 114-124.
6) Shirai Y, Tsukada K, Ohtani T, Watanabe H, Hatakeyama K. Hepatic metastases from carcinoma of the gallbladder. Cancer 1995 ; 75 : 2063-2068.
7) Wakai T, Shirai Y, Sakata J, Nagahashi M, Ajioka Y, Hatakeyama K. Mode of hepatic spread from gallbladder carcinoma : an immunohistochemical analysis of 42 hepatectomized specimens. Am J Surg Pathol 2010 ; 34 : 65-74.
8) Horiguchi A, Miyakawa S, Ishihara S, Miyazaki M, Ohtsuka M, Shimizu H, et al. Gallbladder bed resection or hepatectomy of segments 4a and 5 for pT2 gallbladder carcinoma : analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 518-524.
9) Wakai T, Shirai Y, Sakata J, Tsuchiya Y, Nomura T, Hatakeyama K. Surgical outcomes of minor hepatectomy for locally advanced gallbladder carcinoma. Hepatogastroenterology 2012 ; 59 : 2083-2088.
10) Higuchi R, Ota T, Araida T, Kajiyama H, Yazawa T, Furukawa T, et al. Surgical approaches to advanced gallbladder cancer : a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol 2014 ; 21 : 4308-4316.
P.92 掲載の参考文献
1) 河野博, 中村雅史, 永吉洋介, 森泰寿, 堤宏介, 安井隆晴, 他. 腹腔鏡下胆嚢摘出術におけるIncidental Gallbladder Cancerの頻度. 胆と膵 2011 ; 32 : 373-377.
2) Tian YH, Ji X, Liu B, Yang GY, Meng XF, Xia HT, et al. Surgical treatment of incidental gallbladder cancer discovered during or following laparoscopic cholecystectomy. World J Surg 2015 ; 39 : 746-752.
3) Shirai Y, Yoshida K, Tsukada K, Muto T. Inapparent carcinoma of the gallbladder : an appraisal of a radical second operation after simple cholecystectomy. Ann Surg 1992 ; 215 : 326-331.
4) Ouchi K, Mikuni J, Kakugawa Y ; Organizing Committee, The 30th Annual Congress of the Japanese Society of Biliary Surgery. Laparoscopic cholecystectomy for gallbladder carcinoma : results of a Japanese survey of 498 patients. J Hepatobiliary Pancreat Surg 2002 ; 9 : 256-260.
5) Otero JC, Proske A, Vallilengua C, Lujan M, Poletto L, Pezzotto SM, et al. Gallbladder cancer : surgical results after cholecystectomy in 25 patients with lamina propria invasion and 26 patients with muscular layer invasion. J Hepatobiliary Pancreat Surg 2006 ; 13 : 562-566.
6) Goetze TO, Paolucci V. Immediate re-resection of T1 incidental gallbladder carcinomas : a survival analysis of the German Registry. Surg Endosc 2008 ; 22 : 2462-2465.
7) Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma : analysis of the German Registry. Ann Surg 2008 ; 247 : 104-108.
8) Clemente G, Nuzzo G, De Rose AM, Giovannini I, La Torre G, Ardito F, et al. Unexpected gallbladder cancer after laparoscopic cholecystectomy for acute cholecystitis : a worrisome picture. J Gastrointest Surg 2012 ; 16 : 1462-1468.
9) Steinert R, Nestler G, Sagynaliev E, Muller J, Lippert H, Reymond MA. Laparoscopic cholecystectomy and gallbladder cancer. J Surg Oncol 2006 ; 93 : 682-689.
10) Maker AV, Butte JM, Oxenberg J, Kuk D, Gonen M, Fong Y, et al. Is port site resection necessary in the surgical management of gallbladder cancer? Ann Surg Oncol 2012 ; 19 : 409-417.
11) 島田和明, 奈良聡, 江崎稔, 阪本良弘, 小菅智男. Incidental Gallbladder Cancer術中判明時の対応-術中診断と治療方針-. 胆と膵 2011 ; 32 : 391-396.
12) Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival : a multi-institution analysis from the US extrahepatic biliary malignancy consortium. JAMA Surg 2017 ; 152 : 143-149.
P.95 掲載の参考文献
1) 日本肝胆膵外科学会胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 第2版. 東京, 医学図書出版, 2014, 92-93.
2) 長池幸樹, 千々岩一男, 大内田次郎, 内山周一郎, 今村直哉, 旭吉雅秀, 他. 十二指腸乳頭部癌切除例の臨床病理学的検討. 胆道 2009 ; 23 : 74-79.
3) 大坪出, 味木徹夫, 上野公彦, 沢秀博, 松本逸平, 福本巧, 他. 早期乳頭部癌の臨床的特徴と治療. 胆と膵 2012 ; 33 : 249-254.
4) Ceppa EP, Burbridge RA, Rialon KL, Omotosho PA, Emick D, Jowell PS, et al. Endoscopic versus surgical ampullectomy : an algorithm to treat disease of the ampulla of Vater. Ann Surg 2013 ; 257 : 315-322.
5) Schneider L, Contin P, Fritz S, Strobel O, Buchler MW, Hackert T. Surgical ampullectomy : an underestimated operation in the era of endoscopy. HPB (Oxford) 2016 ; 18 : 65-71
6) Amini A, Miura JT, Jayakrishnan TT, Johnston FM, Tsai S, Christians KK, et al. Is local resection adequate for T1 stage ampullary cancer? HPB (Oxford) 2015 ; 17 : 66-71.
7) Lee H, Park JY, Kwon W, Heo JS, Choi DW, Choi SH. Transduodenal ampullectomy for the treatment of early-stage ampulla of Vater cancer. World J Surg 2016 ; 40 : 967-973.
8) Gao Y, Zhu Y, Huang X, Wang H, Huang X, Yuan Z. Transduodenal ampullectomy provides a less invasive technique to cure early ampullary cancer. BMC Surg 2016 ; 16 : 36.
9) Papalampros A, Moris D, Petrou A, Dimitrokallis N, Karavokyros I, Schizas D, et al. Non-Whipple operations in the management of benign, premalignant and early cancerous duodenal lesions. Anticancer Res 2017 ; 37 : 1443-1452.
10) Zhong J, Palta M, Willett CG, McCall SJ, Bulusu A, Tyler DS, et al. The role of local excision in invasive adenocarcinoma of the ampulla of Vater. J Gastrointest Oncol 2013 ; 4 : 8-13.
11) Kawabata Y, Ishikawa N, Moriyama I, Tajima Y. What is an adequate surgical management for pTis and pT1 early ampullary carcinoma? Hepatogastroenterology 2014 ; 61 : 12-17.
12) Petrone G, Ricci R, Familiari P, Inzani F, Matsuoka M, Mutignani M, et al. Endoscopic snare papillectomy : a possible radical treatment for a subgroup of T1 ampullary adenocarcinomas. Endoscopy 2013 ; 45 : 401-404.
13) Napoleon B, Gincul R, Ponchon T, Berthiller J, Escourrou J, Canard JM, et al. Endoscopic papillectomy for early ampullary tumors : long-term results from a large multicenter prospective study. Endoscopy 2014 ; 46 : 127-134.
14) De Palma GD, Luglio G, Maione F, Esposito D, Siciliano S, Gennarelli N, et al. Endoscopic snare papillectomy : a single institutional experience of a standardized technique : a retrospective cohort study. Int J Surg 2015 ; 13 : 180-183.
15) Alvarez-Sanchez MV, Orial I, Luna OB, Pialat J, Gincul R, Lefort C, et al. Can endoscopic papillectomy be curative for early ampullary adenocarcinoma of the ampulla of Vater? Surg Endosc 2017 ; 31 : 1564-1572.
16) Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York, Springer, 2010.
17) 日本肝胆膵外科学会編. 臨床・病理 胆道癌取扱い規約. 第6版. 東京, 金原出版, 2013, 28-32.
18) 中井陽介, 伊佐山浩通, 笹平直樹, 川久保和道, 木暮宏史, 高原楠昊, 他. 十二指腸乳頭部癌に対する内視鏡的治療の適応と限界. 胆と膵 2012 ; 33 : 255-259.
19) 伊藤啓, 藤田直孝, 野田裕, 小林剛, 洞口淳, 越田真介, 他. 十二指腸乳頭部腫瘍に対する内視鏡を用いた進展度診断. 胆と膵 2012 ; 33 : 233-241.
P.97 掲載の参考文献
1) Nakanishi Y, Zen Y, Kawakami H, Kubota K, Itoh T, Hirano S, et al. Extrahepatic bile duct carcinoma with extensive intraepithelial spread : a clinicopathological study of 21 cases. Mod Pathol 2008 ; 21 : 807-816.
2) Ebata T, Watanabe H, Ajioka Y, Oda K, Nimura Y. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg 2002 ; 89 : 1260-1267.
3) Igami T, Nagino M, Oda K, Nishio H, Ebata T, Yokoyama Y, et al. Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg 2009 ; 249 : 296-302.
4) Shingu Y, Ebata T, Nishio H, Igami T, Shimoyama Y, Nagino M. Clinical value of additional resection of a margin-positive proximal bile duct in hilar cholangiocarcinoma. Surgery 2010 ; 147 : 49-56.
5) Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 2005 ; 103 : 1210-1216.
6) Ojima H, Kanai Y, Iwasaki M, Hiraoka N, Shimada K, Sano T, et al. Intraductal carcinoma component as a favorable prognostic factor in biliary tract carcinoma. Cancer Sci 2009 ; 100 : 62-70.
7) Tsukahara T, Ebata T, Shimoyama Y, Yokoyama Y, Igami T, Sugawara G, et al. Residual carcinoma in situ at the ductal stump has a negative survival effect : an analysis of early-stage cholangiocarcinomas. Ann Surg 2017 ; 266 : 126-132.
8) Higuchi R, Yazawa T, Uemura S, Izumo W, Furukawa T, Yamamoto M. High-grade dysplasia/carcinoma in situ of the bile duct margin in patients with surgically resected node-negative perihilar cholangiocarcinoma is associated with poor survival : a retrospective study. J Hepatobiliary Pancreat Sci 2017 ; 24 : 456-465.
9) Oguro S, Esaki M, Kishi Y, Nara S, Shimada K, Ojima H, et al. Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma. Ann Surg Oncol 2015 ; 22 : 1915-1924.
10) Ribero D, Amisano M, Lo Tesoriere R, Rosso S, Ferrero A, Capussotti L. Additional resection of an intraoperative margin-positive proximal bile duct improves survival in patients with hilar cholangiocarcinoma. Ann Surg 2011 ; 254 : 776-781.
11) Endo I, House MG, Klimstra DS, Gonen M, D'Angelica M, Dematteo RP, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol 2008 ; 15 : 2104-2112.
12) Furukawa T, Higuchi R, Yamamoto M. Clinical relevance of frozen diagnosis of ductal margins in surgery of bile duct cancer. J Hepatobiliary Pancreat Sci 2014 ; 21 : 459-462.
P.99 掲載の参考文献
1) Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996 ; 223 : 384-394.
2) Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma : a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996 ; 224 : 463-473.
3) Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma : a multivariate analysis of prognostic factors. J Clin Oncol 1997 ; 15 : 947-954.
4) Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998 ; 187 : 358-364.
5) Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999 ; 230 : 663-671.
6) Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999 ; 230 : 808-818.
7) Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Okaya T, et al. Parenchyma-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma. J Am Coll Surg 1999 ; 189 : 575-583.
8) Todoroki T, Kawamoto T, Koike N, Takahashi H, Yoshida S, Kashiwagi H, et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 2000 ; 87 : 306-313.
9) Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001 ; 234 : 507-517.
10) Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-140.
11) Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins : results of a prospective study. Ann Surg 2004 ; 240 : 95-101.
12) Aoba T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma : location, number, or ratio of involved nodes. Ann Surg 2013 ; 257 : 718-725.
13) Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 2005 ; 103 : 1210-1216.
14) Ojima H, Kanai Y, Iwasaki M, Hiraoka N, Shimada K, Sano T, et al. Intraductal carcinoma component as a favorable prognostic factor in biliary tract carcinoma. Cancer Sci 2009 ; 100 : 62-70.
15) Igami T, Nagino M, Oda K, Nishio H, Ebata T, Yokoyama Y, et al. Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg 2009 ; 249 : 296-302.
16) Nakanishi Y, Kondo S, Zen Y, Yonemori A, Kubota K, Kawakami H, et al. Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci 2010 ; 17 : 166-173.
17) Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Tajima H, Miwa K. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999 ; 229 : 76-83.
18) Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002 ; 137 : 69-73.
20) DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma : thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007 ; 245 : 755-762.
21) Bahra M, Jacob D, Langrehr JM, Neumann UP, Neuhaus P. Carcinoma of the distal and middle bile duct : surgical results, prognostic factors, and long-term follow-up. J Hepatobiliary Pancreat Surg 2008 ; 15 : 501-507.
22) Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Sueda T. Pancreatoduodenectomy for distal chorangiocartinoma : prognostic impact of lymph node metastasis. World J Surg 2007 ; 31 : 337-342.
24) Kiriyama M, Ebata T, Aoba T, Kaneoka Y, Arai T, Shimizu Y, et al. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg 2015 ; 102 : 399-406.
P.101 掲載の参考文献
1) Pilgrim CH, Groeschl RT, Turaga KK, Gamblin TC. Key factors influencing prognosis in relation to gallbladder cancer. Dig Dis Sci 2013 ; 58 : 2455-2462.
2) Kayahara M, Nagakawa T, Nakagawara H, Kitagawa H, Ohta T. Prognostic factors for gallbladder cancer in Japan. Ann Surg 2008 ; 248 : 807-814.
3) Choi SB, Han HJ, Kim CY, Kim WB, Song TJ, Suh SO, et al. Surgical outcomes and prognostic factors for T2 gallbladder cancer following surgical resection. J Gastrointest Surg 2010 ; 14 : 668-678.
4) Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol 2004 ; 11 : 310-315.
5) Han HS, Cho JY, Yoon YS, Ahn KS, Kim H. Preoperative inflammation is a prognostic factor for gallbladder carcinoma. Br J Surg 2011 ; 98 : 111-116.
6) Wu XS, Shi LB, Li ML, Ding Q, Weng H, Wu WG, et al. Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol 2014 ; 21 : 449-457.
7) Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004 ; 10 : 3131-3136.
8) Shibata K, Uchida H, Iwaki K, Kai S, Ohta M, Kitano S. Lymphatic invasion : an important prognostic factor for stages T1b-T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer. World J Surg 2009 ; 33 : 1035-1041.
9) Butte JM, Matsuo K, Gonen M, D'Angelica MI, Waugh E, Allen PJ, et al. Gallbladder cancer : Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 2011 ; 212 : 50-61.
10) Shindoh J, de Aretxabala X, Aloia TA, Roa JC, Roa I, Zimmitti G, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer : an international multicenter study. Ann Surg 2015 ; 261 : 733-739.
11) Araida T, Yoshikawa T, Azuma T, Ota T, Takasaki K, Hanyu F. Indications for pancreatoduodenectomy in patients undergoing lymphadenectomy for advanced gallbladder carcinoma. J Hepatobiliary Pancreat Surg 2004 ; 11 : 45-49.
12) Shimizu H, Kimura F, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification. J Hepatobiliary Pancreat Surg 2007 ; 14 : 358-365.
13) Higuchi R, Ota T, Araida T, Kajiyama H, Yazawa T, Furukawa T, et al. Surgical approaches to advanced gallbladder cancer : a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol 2014 ; 21 : 4308-4316.
14) Shimada H, Endo I, Sugita M, Masunari H, Fujii Y, Tanaka K, et al. Hepatic resection combined with portal vein or hepatic artery reconstruction for advanced carcinoma of the hilar bile duct and gallbladder. World J Surg 2003 ; 27 : 1137-1142.
15) Yamamoto Y, Sugiura T, Ashida R, Okamura Y, Ito T, Uesaka K. Indications for major hepatectomy and combined procedures for advanced gallbladder cancer. Br J Surg 2017 ; 104 : 257-266.
16) Kobayashi A, Oda T, Fukunaga K, Sasaki R, Ohkohchi N. Invasion of the hepatic artery is a crucial predictor of poor outcomes in gallbladder carcinoma. World J Surg 2012 ; 36 : 645-650.
17) Ito H, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, et al. Accurate staging for gallbladder cancer : implications for surgical therapy and pathological assessment. Ann Surg 2011 ; 254 : 320-325.
18) Negi SS, Singh A, Chaudhary A. Lymph nodal involvement as prognostic factor in gallbladder cancer : location, count or ratio? J Gastrointest Surg 2011 ; 15 : 1017-1025.
19) Shibata K, Uchida H, Iwaki K, Kai S, Ohta M, Kitano S. Lymphatic invasion : An important prognostic factor for Stages T1b-T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer. World J Surg 2009 ; 33 : 1035-1041.
20) Yamaguchi R, Nagino M, Oda K, Kamiya J, Uesaka K, Nimura Y. Perineural invasion has a negative impact on survival of patients with gallbladder carcinoma. Br J Surg 2002 ; 89 : 1130-1136.
21) Ohtsuka M, Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, et al. Routes of hepatic metastasis of gallbladder carcinoma. Am J Clin Pathol 1998 ; 109 : 62-68.
22) Endo I, Shimada H, Takimoto A, Fujii Y, Miura Y, Sugita M, et al. Microscopic liver metastasis : prognostic factor for patients with pT2 gallbladder carcinoma. World J Surg 2004 ; 28 : 692-696.
23) Endo I, Shimada H, Tanabe M, Fujii Y, Takeda K, Morioka D, et al. Prognostic significance of the number of positive lymph nodes in gallbladder cancer. J Gastrointest Surg 2006 ; 10 : 999-1007.
24) Sakata J, Shirai Y, Wakai T, Ajioka Y, Hatakeyama K. Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma. Ann Surg Oncol 2010 ; 17 : 1831-1840.
25) Shirai Y, Sakata J, Wakai T, Ohashi T, Ajioka Y, Hatakeyama K. Assessment of lymph node status in gallbladder cancer : location, number, or ratio of positive nodes. World J Surg Oncol 2012 ; 10 : 87.
28) Lee JM, Kim BW, Kim WH, Wang HJ, Kim MW. Clinical implication of bile spillage in patients undergoing laparoscopic cholecystectomy for gallbladder cancer. Am Surg 2011 ; 77 : 697-701.
29) Ouchi K, Mikuni J, Kakugawa Y ; Organizing Committee, The 30th Annual Congress of the Japanese Society of Biliary Surgery. Laparoscopic cholecystectomy for gallbladder carcinoma : results of a Japanese survey of 498 patients. J Hepatobiliary Pancreat Surg 2002 ; 9 : 256-260.
30) Steinert R, Nestler G, Sagynaliev E, Muller J, Lippert H, Reymond MA. Laparoscopic cholecystectomy and gallbladder cancer. J Surg Oncol 2006 ; 93 : 682-689.
31) Pawlik TM, Gleisner AL, Vigano L, Kooby DA, Bauer TW, Frilling A, et al. Incidence of finding residual disease for incidental gallbladder carcinoma : implications for re-resection. J Gastrointest Surg 2007 ; 11 : 1478-1486.
32) Lendoire JC, Gil L, Duek F, Quarin C, Garay V, Raffin G, et al. Relevance of residual disease after liver resection for incidental gallbladder cancer. HPB (Oxford) 2012 ; 14 : 548-553.
33) Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg 2011 ; 15 : 1007-1016.
34) Garg PK, Pandey D, Sharma J. The surgical management of gallbladder cancer. Expert Rev Gastroenterol Hepatol 2015 ; 9 : 155-166.
P.104 掲載の参考文献
1) 久保木知, 清水宏明, 大塚将之, 加藤厚, 宮崎勝. 膵癌・胆道癌-基礎と臨床の最新動向-乳頭部癌予後 長期生存に関わる予後因子. 日本臨牀 2015 ; 73 : 749-753.
2) Chan C, Herrera MF, de la Garza L, Quintanilla-Martinez L, Vargas-Vorackova F, Richaud-Patin Y, et al. Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg 1995 ; 222 : 632-637.
3) 石原慎, 宮川秀一, 堀口明彦, 宮崎勝, 高田忠敬. 胆道癌登録からみた乳頭部癌の動向-進行度とリンパ節転移を中心に-. 胆と膵 2012 ; 33 : 221-224.
4) Brierley JD, Gospodarowicz MK, Wittekind Ch, eds. TNM classification of malignant tumours. 8th ed. New York : Wiley-Blackwell ; 2017.
5) Shirai Y, Ohtani T, Tsukada K, Hatakeyama K. Patterns of lymphatic spread of carcinoma of the ampulla of Vater. Br J Surg 1997 ; 84 : 1012-1016.
6) Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Miyazaki I. Surgical strategy for carcinoma of the papilla of Vater on the basis of on the lymphatic spread and mode of recurrence. Surgery 1997 ; 121 : 611-617.
7) Mizuno T, Ishizaki Y, Ogura K, Yoshimoto J, Kawasaki S. Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater. Br J Surg 2006 ; 93 : 221-225.
8) Hornick JR, Johnston FM, Simon PO, Younkin M, Chamberlin M, Mitchem JB, et al. A single-institution review of 157 patients presenting with benign and malignant tumors of the ampulla of Vater : management and outcomes. Surgery 2011 ; 150 : 169-176.
9) Sierzega M, Nowak K, Kulig J, Matyja A, Nowak W, Popiela T. Lymph node involvement in ampullary cancer : the importance of the number, ratio, and location of metastatic nodes. J Surg Oncol 2009 ; 100 : 19-24.
10) Sakata J, Shirai Y, Wakai T, Ajioka Y, Akazawa K, Hatakeyama K. Assessment of the nodal status in ampullary carcinoma : the number of positive lymph nodes versus the lymph node ratio. World J Surg 2011 ; 35 : 2118-2124.
11) de Paiva Haddad LB, Patzina RA, Penteado S, Montagnini AL, da Cunha JE, Machado MC, et al. Lymph node involvement and not the histopathologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of Vater. J Gastrointest Surg 2010 ; 14 : 719-728.
12) Ohike N, Coban I, Kim GE, Basturk O, Tajiri T, Krasinskas A, et al. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol 2010 ; 34 : 1417-1424.
13) Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol 2010 ; 17 : 991-997.
P.107 掲載の参考文献
1) Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med 1979 ; 301 : 1364-1369.
2) Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998 ; 280 : 1747-1751.
3) Farges O, Goutte N, Bendersky N, Falissard B. Incidence and risks of liver resection : an all-inclusive French nationwide study. Ann Surg 2012 ; 256 : 697-704.
4) Hata T, Motoi F, Ishida M, Naitoh T, Katayose Y, Egawa S, et al. Effect of hospital volume on surgical outcomes after pancreaticoduodenectomy : a systematic review and meta-analysis. Ann Surg 2016 ; 263 : 664-672.
5) Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005 ; 242 : 540-544.
6) Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB, Meropol NJ. Centralization of cancer surgery : implications for patient access to optimal care. J Clin Oncol 2009 ; 27 : 4671-4678.
7) de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, et al. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 2012 ; 99 : 404-410.
8) O'Mahoney PRA, Yeo HL, Sedrakyan A, Trencheva K, Mao J, Isaacs AJ, et al. Centralization of pancreatoduodenectomy a decade later : impact of the volume-outcome relationship. Surgery 2016 ; 159 : 1528-1538.
9) Yasunaga H, Horiguchi H, Matsuda S, Fushimi K, Hashimoto H, Ohe K, et al. Relationship between hospital volume and operative mortality for liver resection : data from the Japanese Diagnosis Procedure Combination database. Hepatol Res 2012 ; 42 : 1073-1080.
10) Yoshioka R, Yasunaga H, Hasegawa K, Horiguchi H, Fushimi K, Aoki T, et al. Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy. Br J Surg 2014 ; 101 : 523-529.
11) Miura F, Yamamoto M, Gotoh M, Konno H, Fujimoto J, Yanaga K, et al. Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the National Clinical Database of Japan : part 1-Hepatectomy of more than one segment. J Hepatobiliary Pancreat Sci 2016 ; 23 : 313-323.
12) Miura F, Yamamoto M, Gotoh M, Konno H, Fujimoto J, Yanaga K, et al. Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the National Clinical Database of Japan : part 2-Pancreatoduodenectomy. J Hepatobiliary Pancreat Sci 2016 ; 23 : 353-363.
13) Otsubo T, Kobayashi S, Sano K, Misawa T, Ota T, Katagiri S, et al. Safety-related outcomes of the Japanese Society of Hepato-Biliary-Pancreatic Surgery board certification system for expert surgeons. J Hepatobiliary Pancreat Sci 2017 ; 24 : 252-261.

第VII章. 化学療法

P.112 掲載の参考文献
3) Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 2008 ; 62 : 849-855.
4) Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours : a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer 2009 ; 101 : 621-627.
5) Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-1281.
6) Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 2010 ; 103 : 469-474.
7) Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer : a meta-analysis of two randomised trials. Ann Oncol 2014 ; 25 : 391-398.
8) Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer : a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 2013 ; 104 : 1211-1216.
9) Mizusawa J, Morizane C, Okusaka T, Katayama H, Ishii H, Fukuda H, et al. Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer : Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol 2016 ; 46 : 385-388.
10) Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer : a randomized controlled study. J Clin Oncol 2010 ; 28 : 4581-4586.
11) Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer : a Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). 2018 Gastrointestinal Cancers Symposium. #205
12) Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol 2015 ; 75 : 293-300.
13) Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, Seo S, et al : Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). 2018 ESMO annual meeting. #6150.
14) Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer : a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012 ; 13 : 181-188.
15) Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO) : a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014 ; 15 : 819-828.
16) Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol 2015 ; 26 : 943-949.
17) Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03) : a randomised phase 2 trial. Lancet Oncol 2015 ; 16 : 967-978.
18) Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer : A randomized phase 2 trial (Vecti-BIL study). Cancer 2016 ; 122 : 574-581.
19) Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer : Federation Francophone de Cancerologie Digestive 9902 phase II randomised study. Eur J Cancer 2014 ; 50 : 2975-2982.
P.115 掲載の参考文献
1) Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 2013 ; 71 : 1141-1146.
2) Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012 ; 30 : 708-713.
3) Kim RD, McDonough SL, El-Khoueiry AB, Bekali-Saab TS, Stein S, Sahai V, et al. SWOG S1310 : Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer. J Clin Oncol 2017 ; 35 suppl : 4016.
4) Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017 ; 357 : 409-413.
5) Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009 ; 76 : 254-261.
6) Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009 ; 32 : 348-352.
7) He S, Shen J, Sun X, Liu L, Dong J. A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother 2014 ; 26 : 243-247.
8) Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, et al. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011 ; 29 : 1488-1493.
9) Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007 ; 72 : 105-110.
10) Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma : a multicentre, multinational study. Eur J Cancer 2012 ; 48 : 196-201.
11) Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, et al : Efficacy and ssafety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Sci 2018 ; 109 : 215-224.
12) Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, et al. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer 2017 ; 116 : 1402-1407.
13) Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 2018 ; 36 : 276-282.
14) Mazzaferro V, El-Rayes BF, Cotsoglou C, Harris WP, Damjanov N, Masi G, et al. ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J Clin Oncol 2017 ; 35 suppl : 4017.
15) Soria JC, Strickler JH, Govindan R, Chai S, Chan N, Quiroga-Garcia V, et al. Safety and activity of the panfibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with molecularly selected advanced cholangiocarcinoma. J Clin Oncol 2017 ; 35 suppl : 4074.
16) Buzzoni R, Pusceddu S, Bajetta E, De Braud F, Platania M, Iannacone C, et al. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy : a phase II ITMO study. Ann Oncol 2014 ; 25 : 1597-1603.
17) Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mossner J, et al. Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer : a bicentric phase II study. Onkologie 2011 ; 34 : 469-470.
18) Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, et al. Phase II study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Br J Cancer 2017 ; 117 : 189-194.
19) Bang YJ, Doi T, Braud FD, Piha-Paul S, Hollebecque A, Razak ARA, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients with advanced biliary tract cancer : interim results of KEYNOTE-028. Eur J Cancer 2015 ; 51 : S112.
20) Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011 ; 29 : 1066-1072.
P.118 掲載の参考文献
1) Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? : a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002 ; 95 : 1685-1695.
2) Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma. JAMA 2012 ; 308 : 147-156.
3) Edeline J, Bonnetain F, Phelip JM, Watelet J, Hammel P, Joly JP, et al. Gemox versus surveillance following surgery of localized biliary tract cancer ; Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol 2017 ; 35 suppl : 225.
4) Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, et al. Adjuvant capecitabine for biliary tract cancer : the BILCAP randomized study. J Clin Oncol 2017 ; 35 suppl : 4006.
5) Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018 ; 105 : 192-202.
6) Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol 2012 ; 30 : 1934-1940.
7) Ikeda M, Nakachi K, Konishi M, Mitsunaga S, Mizusawa J, Uesaka K, et al. A randomized phase III trial comparing adjuvant chemotherapy with S-1 vs surgery alone in patients with resectable biliary tract cancer : JCOG 1202 (ASCOT). J Clin Oncol 2017 ; 35 suppl : 4144.
8) Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klumpen HJ, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) : a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 2015 ; 15 : 564.
P.120 掲載の参考文献
2) Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 2008 ; 62 : 849-855.
3) Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-1281.
4) Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 2010 ; 103 : 469-474.
5) Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer : a meta-analysis of two randomized trials. Ann Oncol 2014 ; 25 : 391-398.
6) Mizusawa J, Morizane C, Okusaka T, Katayama H, Ishii H, Fukuda H, et al. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer : Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol 2016 ; 46 : 385-388.
7) Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction : Cancer and Leukemia Group B 9565. J Clin Oncol 2000 ; 18 : 2780-2787.
8) Shibata T, Ebata T, Fujita K, Shimokata T, Maeda O, Mitsuma A, et al. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Cancer Sci 2016 ; 107 : 168-172.
9) Lamarca A, Benafif S, Ross P, Bridgewater J, Valle JW. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting : effective intervention in patients with luminal disease. Eur J Cancer 2015 ; 51 : 1694-1703.

第VIII章. 放射線治療

P.128 掲載の参考文献
1) Shinchi H, Takao S, Nishida H, Aikou T. Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol 2000 ; 75 : 89-94.
2) Shinohara ET, Mitra N, Guo M, Metz JM. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009 ; 74 : 1191-1198.
3) Isayama H, Tsujino T, Nakai Y, Sasaki T, Nakagawa K, Yamashita H, et al. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma. World J Gastroenterol 2012 ; 18 : 2364-2370.
4) Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994 ; 28 : 945-951.
5) Valek V, Kysela P, Kala Z, Kiss I, Tomasek J, Petera J. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma : a prospective randomised study. Eur J Radiol 2007 ; 62 : 175-179.
6) Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, et al. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 2003 ; 57 : 1357-1365.
7) Shinohara ET, Guo M, Mitra N, Metz JM. Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2010 ; 78 : 722-728.
8) Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Kanesaka N, Tamamoto T, et al. Impact of intraluminal brachytherapy on survival outcome for radiation therapy for unresectable biliary tract cancer : a propensity-score matched-pair analysis. Int J Radiat Oncol Biol Phys 2014 ; 89 : 822-829.
9) Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996 ; 39 : 852-855.
10) Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011 ; 79 : 158-162.
11) Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer 2015 ; 6 : 1099-1104.
12) Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, et al. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol 2016 ; 1 : 237-243.
13) Kopek N, Holt MI, Hansen AT, Hoyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010 ; 94 : 47-52.
14) Momm F, Schubert E, Henne K, Hodapp N, Frommhold H, Harder J, et al. Stereotactic fractionated radiotherapy for Klatskin tumours. Radiother Oncol 2010 ; 95 : 99-102.
15) Polistina FA, Guglielmi R, Baiocchi C, Francescon P, Scalchi P, Febbraro A, et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol 2011 ; 99 : 120-123.
16) Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma : a retrospective dose response analysis. J Clin Oncol 2016 ; 34 : 219-226.
17) Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016 ; 34 : 460-468.
18) Ohkawa A, Mizumoto M, Ishikawa H, Abei M, Fukuda K, Hashimoto T, et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. J Gastroenterol Hepatol 2015 ; 30 : 957-963.
19) Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Ishikawa Y, et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol 2014 ; 9 : 26.
20) Abe T, Shibuya K, Koyama Y, Okamoto M, Kiyohara H, Katoh H, et al. Initial results of hypofractionated carbon ion radiotherapy for cholangiocarcinoma. Anticancer Res 2016 ; 36 : 2955-2960.
21) Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997 ; 39 : 929-935.
22) Brunner TB, Schwab D, Meyer T, Sauer R. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma : a retrospective analysis. Strahlenther Onkol 2004 ; 180 : 751-757.
23) Akita H, Yamada T, Sasaki Y, Eguchi H, Ohigashi H, Ishikawa O, et al. The evaluation of chemoradiotherapy to unresectable hepatobiliary cancers. Gan To Kagaku Ryoho 2005 ; 32 : 1727-1729. (in Japanese)
24) Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002 ; 53 : 969-974.
25) Matsumoto S, Kiyosue H, Komatsu E, Wakisaka M, Tomonari K, Hori Y, et al. Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma. Cancer 2004 ; 100 : 2422-2429.
26) Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, et al. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol 2005 ; 28 : 234-241.
27) Park JY, Park SW, Chung JB, Seong J, Kim KS, Lee WJ, et al. Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. Am J Clin Oncol 2006 ; 29 : 240-245.
28) Autorino R, Mattiucci GC, Ardito F, Balducci M, Deodato F, Macchia G, et al. Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma : long-term results of a phase II study. Anticancer Res 2016 ; 36 : 737-740.
29) Lee KJ, Yi SW, Cha J, Seong J, Bang S, Song SY, et al. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Cancer Chemother Pharmacol 2016 ; 78 : 841-846.
30) Isohashi F, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T, et al. Patterns of radiotherapy practice for biliary tract cancer in Japan : results of the Japanese radiation oncology study group (JROSG) survey. Radiat Oncol 2013 ; 8 : 76.
31) Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T, et al. Factors influencing survival outcome for radiotherapy for biliary tract cancer : a multicenter retrospective study. Radiother Oncol 2014 ; 110 : 546-552.
32) Pollom EL, Alagappan M, Park LS, Whittemore AS, Koong AC, Chang DT. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med 2017 ; 6 : 129-141.
33) Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer : Federation Francophone de Cancerologie Digestive 9902 phase II randomised study. Eur J Cancer 2014 ; 50 : 2975-2982.
P.133 掲載の参考文献
1) Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995 ; 221 : 788-797.
3) Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma : postresection radiotherapy improves survival. Eur J Surg Oncol 2007 ; 33 : 202-207.
4) Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 2005 ; 35 : 548-552.
5) Bonet Beltran M, Allal AS, Gich I, Gich I, Sole JM, Carrio I. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? : a systematic review with a meta-analysis of observational studies. Cancer Treat Rev 2012 ; 38 : 111-119.
6) Shinohara ET, Mitra N, Guo M, Metz JM. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009 ; 74 : 1191-1198.
7) Wang SJ, Fuller CD, Kim JS, Sittig DF, Thomas CR Jr, Ravdin PM. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol 2008 ; 26 : 2112-2117.
8) Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 2007 ; 96 : 8-13.
9) Vern-Gross TZ, Shivnani AT, Chen K, Lee CM, Tward JD, MacDonald OK, et al. Survival outcomes in resected extrahepatic cholangiocarcinoma : effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys 2011 ; 81 : 189-198.
10) Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000 ; 46 : 581-587.
11) Nakano K, Chijiiwa K, Toyonaga T, Ueda J, Takamatsu Y, Kimura M, et al. Combination therapy of resection and intraoperative radiation for patients with carcinomas of extrahepatic bile duct and ampulla of Vater : prognostic advantage over resection alone? Hepatogastroenterology 2003 ; 50 : 928-933.
12) Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T, et al. Factors influencing survival outcome for radiotherapy for biliary tract cancer : a multicenter retrospective study. Radiother Oncol 2014 ; 110 : 546-552.
13) Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, et al. Extrahepatic bile duct adenocarcinoma : patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008 ; 15 : 3147-3156.
14) Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007 ; 68 : 178-182.
15) Lim KH, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy : which is better in patients with radically resected extrahepatic biliary tract cancer? : a non-randomized, single center study. BMC Cancer 2009 ; 9 : 345.
16) Im JH, Seong J, Lee IJ, Park JS, Yoon DS, Kim KS, et al. Surgery alone versus surgery followed by chemotherapy and radiotherapy in resected extrahepatic bile duct cancer : treatment outcome analysis of 336 patients. Cancer Res Treat 2016 ; 48 : 583-595.
17) Kim YS, Hwang IG, Park SE, Go SI, Kang JH, Park I, et al. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Cancer Chemother Pharmacol 2016 ; 77 : 979-985.
18) Hoehn RS, Wima K, Ertel AE, Meier A, Ahmad SA, Shah SA, et al. Adjuvant therapy for gallbladder cancer : an analysis of the National Cancer Data Base. J Gastrointest Surg 2015 ; 19 : 1794-1801.
19) Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol 2012 ; 30 : 1934-1940.
20) Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809 : A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 2015 ; 33 : 2617-2622.
21) Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma : the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol 2011 ; 6 : 126.
22) Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation : long-term results of EORTC trial 40891. Ann Surg 2007 ; 246 : 734-740.
23) Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, et al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer : a prospective randomized controlled trial. Ann Surg 2008 ; 248 : 1031-1041.
24) Morak MJ, Pek CJ, Kompanje EJ, Hop WC, Kazemier G, van Eijck CH. Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer : a prospective randomized controlled study. Cancer 2010 ; 116 : 830-836.
25) Acharya A, Markar SR, Sodergren MH, Malietzis G, Darzi A, Athanasiou T, et al. Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. Br J Surg 2017 ; 104 : 814-822.
26) Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012 ; 143 : 88-98.
27) Marchan EM, Landry JC. Neoadjuvant chemoradiation followed by orthotopic liver transplantation in cholangiocarcinomas : the Emory experience. J Gastrointest Oncol 2016 ; 7 : 248-254.
28) McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997 ; 174 : 605-608.
29) Kobayashi S, Tomokuni A, Gotoh K, Takahashi H, Akita H, Marubashi S, et al. A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. Eur J Surg Oncol 2017 ; 43 : 763-771.
P.136 掲載の参考文献
1) Nanashima A, Nagayasu T. Current status of photodynamic therapy in digestive tract carcinoma in Japan. Int J Mol Sci 2015 ; 16 : 3434-3440.
2) Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma : a randomized prospective study. Gastroenterology 2003 ; 125 : 1355-1363.
3) Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer : improved survival after photodynamic therapy. Am J Gastroenterol 2005 ; 100 : 2426-2430.
4) Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma : palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006 ; 244 : 230-239.
5) Leggett CL, Gorospe EC, Murad MH, Montori VM, Baron TH, Wang KK. Photodynamic therapy for unresectable cholangiocarcinoma : a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn Ther 2012 ; 9 : 189-195.
6) Cheon YK, Lee TY, Lee SM, Yoon JY, Shim CS. Long-term outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford) 2012 ; 14 : 185-193.
7) Dolak W, Schwaighofer H, Hellmich B, Stadler B, Spaun G, Plieschnegger W, et al. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction : a nationwide retrospective study of 150 consecutive applications. United European Gastroenterol J 2017 ; 5 : 104-110.
8) Gao F, Bai Y, Ma SR, Liu F, Li ZS. Systematic review : photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2010 ; 17 : 125-131.
9) Moole H, Tathireddy H, Dharmapuri S, Moole V, Boddireddy R, Yedama P, et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma : a systematic review and meta-analysis. World J Gastroenterol 2017 ; 23 : 1278-1288.
10) Lu Y, Liu L, Wu JC, Bie LK, Gong B. Efficacy and safety of photodynamic therapy for unresectable cholangiocarcinoma : a meta-analysis. Clin Res Hepatol Gastroenterol 2015 ; 39 : 718-724.
11) Hong MJ, Cheon YK, Lee EJ, Lee TY, Shim CS. Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma. Gut Liver 2014 ; 8 : 318-323.
12) Park DH, Lee SS, Park SE, Lee JL, Choi JH, Choi HJ, et al. Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. Eur J Cancer 2014 ; 50 : 1259-1268.
13) Wentrup R, Winkelmann N, Mitroshkin A, Prager M, Voderholzer W, Schachschal G, et al. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver 2016 ; 10 : 470-475.
14) Nanashima A, Isomoto H, Abo T, Nonaka T, Morisaki T, Arai J, et al. How to access photodynamic therapy for bile duct carcinoma. Ann Transl Med 2014 ; 2 : 23.
15) Wagner A, Wiedmann M, Tannapfel A, Mayr C, Kiesslich T, Wolkersdorfer GW, et al. Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy-Long-Term Outcome of a Phase II Pilot Study. Int J Mol Sci 2015 ; 16 : 26619-26628.
16) Wagner A, Denzer UW, Neureiter D, Kiesslich T, Puespoeck A, Rauws EA, et al. Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma : A multicenter prospective phase II study. Hepatology 2015 ; 62 : 1456-1465.

第IX章. 病理

P.145 掲載の参考文献
1) Krones E, Graziadei I, Trauner M, Fickert P. Evolving concepts in primary sclerosing cholangitis. Liver Int 2012 ; 32 : 352-369.
2) Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan--analysis of 192 cases. J Gastroenterol 1997 ; 32 : 134-137.
3) Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int 2008 ; 28 : 983-989.
4) Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001 ; 15 : 629-642.
5) Zauli D, Schrumpf E, Crespi C, Cassani F, Fausa O, Aadland E. An autoantibody profile in primary sclerosing cholangitis. J Hepatol 1987 ; 5 : 14-18.
6) Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa S, Kamisawa T, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 2012 ; 19 : 536-542.
7) IgG4関連硬化性胆管炎臨床診断基準作成ワーキンググループ. IgG4関連硬化性胆管炎臨床診断基準 2012. 胆道 2012 ; 26 : 59-63.
8) Zen Y, Harada K, Sasaki M, Sato Y, Tsuneyama K, Haratake J, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis : do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 2004 ; 28 : 1193-1203.
9) Nakanuma Y, Zen Y, Portmann BC. Diseases of the bile ducts. MacSween's Pathology of the Liver (Eds. Burt A, Portmann B, Ferrell L) 6th eds., Churchill Livingstone, 2011, pp.491-562.
10) Harada K, Shimoda S, Kimura Y, Sato Y, Ikeda H, Igarashi S, et al. Significance of immunoglobulin G4 (IgG4) -positive cells in extrahepatic cholangiocarcinoma : molecular mechanism of IgG4 reaction in cancer tissue. Hepatology 2012 ; 56 : 157-164.
11) Zen Y, Fujii T, Sato Y, Masuda S, Nakanuma Y. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease. Mod Pathol 2007 ; 20 : 884-894.
12) Albores-Saavedra J, Angeles-Angeles A. Diseases of the gallbladder. MacSween's Pathology of the Liver (Eds. Burt A, Portmann B, Ferrell L) 6th eds., Churchill Livingstone, 2011, pp.563-597.
13) Sawada S, Harada K, Isse K, Sato Y, Sasaki M, Kaizaki Y, et al. Involvement of Escherichia coli in pathogenesis of xanthogranulomatous cholecystitis with scavenger receptor class A and CXCL16-CXCR6 interaction. Pathol Int 2007 ; 57 : 652-663.
14) 萱原正都, 中川原寿俊, 北川裕久, 太田哲生. 胆管末端部のadenomyomatosisの診断と治療. 胆道 2010 ; 24 : 192-198.
15) Nishimura A, Shirai Y, Hatakeyama K. Segmental adenomyomatosis of the gallbladder predisposes to cholecystolithiasis. J Hepatobiliary Pancreat Surg 2004 ; 11 : 342-347.
16) 羽賀敏博, 吉澤忠司, 鬼島宏. 腫瘍様病変 (ポリープを含む) および腺筋腫症. 鬼島宏, 福嶋敬宜 (編) : 腫瘍病理鑑別診断アトラス 胆道癌・膵癌. 文光堂, 2015.
17) 鬼島宏 : 胆嚢・胆管. 向井清, 真鍋俊明, 深山正久 (編) : 外科病理学, 第4版. 文光堂, 東京, 2006, pp. 665-698.
18) 吉澤忠司, 鬼島宏 : 腺腫. 坂元亨宇, 平岡伸介, 尾島英知 (編) : 癌診療指針のための病理診断プラクティス 肝・胆・膵腫瘍. 中山書店, 2014.
19) Bosman FT, Carneiro F, Hruban RH, Theise ND, eds : WHO Classification of Tumours of the Digestive System. Forth Edition. IARC Press, Lyon, 2010, pp. 263-278 (Chapter 11, Tumours of the Gallbladder and Extrahepatic Bile Ducts).
20) Hamilton SR, Aaltonen LA, eds : Pathology and Genetics. Tumours of the Digestive System. World Health Organization Classification of Tumours. IARC Press, Lyon, 2000, pp. 203-217 (Chapter 9, Tumours of the Gallbladder and Extrahepatic Bile Ducts).
21) Handra-Luca A, Terris B, Couvelard A, Bonte H, Flejou JF. Adenomyoma and adenomyomatous hyperplasia of the Vaterian system : clinical, pathological, and new immunohistochemical features of 13 cases. Mod Pathol 2003 ; 16 : 530-536.
22) Carpino G, Cardinale V, Onori P, Franchitto A, Berloco PB, Rossi M, et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intrahepatic bile ducts : an anatomical in situ study yielding evidence of maturational lineages. J Anat 2012 ; 220 : 186-199.
P.149 掲載の参考文献
1) Nakanishi Y, Zen Y, Kondo S, Itoh T, Itatsu K, Nakanuma Y. Expression of cell cycle-related molecules in biliary premalignant lesions : biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol 2008 ; 39 : 1153-1161.
2) Itatsu K, Zen Y, Ohira S, Ishikawa A, Sato Y, Harada K, et al. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int 2007 ; 27 : 1174-1184.
3) Nakanuma Y, Kakuda Y, Uesaka K, Miyata T, Yamamoto Y, Fukumura Y, et al. Characterization of intraductal papillary neoplasm of bile duct with respect to histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm. Hum Pathol 2016 ; 51 : 103-113.
4) 福村由紀, 大池信之, 中沼安二, 八尾隆史. 胆道癌の前癌病変 (IPNB, BilIN, ICPNを含む). 鬼島宏, 福嶋敬宜 (編) : 腫瘍病理鑑別診断アトラス「胆道癌・膵癌」. 文光堂, 2015 ; pp 66-75.
5) Tsukahara T, Shimoyama Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, et al. Cholangiocarcinoma with intraductal tubular growth pattern versus intraductal papillary growth pattern. Mod Pathol 2016 ; 29 : 293-301.
6) Onoe S, Shimoyama Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, et al. Clinicopathological significance of mucin production in patients with papillary cholangiocarcinoma. World J Surg 2015 ; 39 : 1177-1184.
7) Onoe S, Shimoyama Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, et al. Prognostic delineation of papillary cholangiocarcinoma based on the invasive proportion : a single-institution study with 184 patients. Surgery 2014 ; 155 : 280-291.
8) Tsai JH, Liau JY, Yuan CT, Cheng ML, Yuan RH, Jeng YM. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct. Histopathology 2017 ; 70 : 756-765.
9) Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. Lyon : International Agency for Research on Cancer, 2010.
10) Adsay V, Jang KT, Roa JC, Dursun N, Ohike N, Bagci P, et al. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are > 1.0 cm) : clinicopathologic and immunohistochemical analysis of 123 cases. Am J Surg Pathol 2012 ; 36 : 1279-1301.
11) Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct : an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 2006 ; 44 : 350-358.
12) Sato Y, Harada K, Sasaki M, Nakanuma Y. Histological characterization of biliary intraepithelial neoplasia with respect to pancreatic intraepithelial neoplasia. Int J Hepatol 2014 ; 2014 : 678260.
13) Matthaei H, Lingohr P, Strasser A, Dietrich D, Rostamzadeh B, Glees S, et al. Biliary intraepithelial neoplasia (BilIN) is frequently found in surgical margins of biliary tract cancer resection specimens but has no clinical implications. Virchows Arch 2015 ; 466 : 133-141.
14) Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010 ; 34 : 27-34.
15) Rougemont AL, Genevay M, McKee TA, Gremaud M, Mentha G, Rubbia-Brandt L. Extensive biliary intraepithelial neoplasia (BilIN) and multifocal early intrahepatic cholangiocarcinoma in non-biliary cirrhosis. Virchows Arch 2010 ; 456 : 711-717.
16) Torbenson M, Yeh MM, Abraham SC. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. Am J Surg Pathol 2007 ; 31 : 1410-1413.
17) Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013 ; 119 : 1669-1674.
18) Aishima S, Iguchi T, Fujita N, Taketomi A, Maehara Y, Tsuneyoshi M, et al. Histological and immunohistological findings in biliary intraepithelial neoplasia arising from a background of chronic biliary disease compared with liver cirrhosis of non-biliary aetiology. Histopathology 2011 ; 59 : 867-875.
19) Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma : a light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol 1994 ; 18 : 1078-1091.
20) Sato Y, Sasaki M, Harada K, Aishima S, Fukusato T, Ojima H, et al. Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia. J Gastroenterol 2014 ; 49 : 64-72.
21) Hamilton SR, Aaltonen LA, eds : Pathology and Genetics. Tumours of the Digestive System. World Health Organization Classification of Tumours. IARC Press, Lyon, 2000, pp. 203-217 (Chapter 9, Tumours of the Gallbladder and Extrahepatic Bile Ducts).
22) 鬼島宏, 羽賀敏博, 高綱将史, 太田理恵, 袴田健一, 福田眞作. 胆嚢癌の前癌病変. 日消誌 2015 ; 112 : 437-443.
23) Jang KT, Ahn S. Tumoral versus flat intraepithelial neoplasia of pancreatobiliary tract, gallbladder, and ampulla of Vater. Arch Pathol Lab Med 2016 ; 140 : 429-436.
25) Stancu M, Caruntu ID, Giusca S, Dobrescu G. Hyperplasia, metaplasia, dysplasia and neoplasia lesions in chronic cholecystitis - a morphologic study. Rom J Morphol Embryol 2007 ; 48 : 335-342.
26) Duarte I, Llanos O, Domke H, Harz C, Valdivieso V. Metaplasia and precursor lesions of gallbladder carcinoma : frequency, distribution, and probability of detection in routine histologic samples. Cancer 1993 ; 72 : 1878-1884.
27) Laitio M. Histogenesis of epithelial neoplasms of human gallbladder I. Dysplasia. Pathol Res Pract 1983 ; 178 : 51-56.
28) Stancu M, Caruntu ID, Sajin M, Giusca S, Badescu A, Dobrescu G. Immunohistochemical markers in the study of gallbladder premalignant lesions and cancer. Rev Med Chir Soc Med Nat Iasi 2007 ; 111 : 734-743.
29) Kim SW, Her KH, Jang JY, Kim WH, Kim YT, Park YH. K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. J Surg Oncol 2000 ; 75 : 246-251.
30) Choi HJ, Yun SS, Kim HJ, Choi JH. Expression of p16 protein in gallbladder carcinoma and its precancerous conditions. Hepatogastroenterology 2010 ; 57 : 18-21.
31) Lynch BC, Lathrop SL, Ye D, Ma TY, Cerilli LA. Expression of the p16 (INK4a) gene product in premalignant and malignant epithelial lesions of the gallbladder. Ann Diagn Pathol 2008 ; 12 : 161-164.
32) Legan M, Luzar B, Marolt VF, Cor A. Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 2006 ; 12 : 3425-3429.
33) Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions : an immunohistochemical study. Hum Pathol 1996 ; 27 : 360-365.
34) Wee A, Teh M, Raju GC. Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesions. J Clin Pathol 1994 ; 47 : 453-456.
35) Moreno M, Pimentel F, Gazdar AF, Wistuba II, Miquel JF. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol 2005 ; 4 : 192-199.
36) Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001 ; 169 : 59-68.
37) Inada A, Konishi F, Yamamichi N, Ito H. Histogenesis of gallbladder cancer with special reference to metaplastic changes and distribution of various mucins and CEA. Nihon Geka Gakkai Zasshi 1989 ; 90 : 894-906.
38) Yamagiwa H, Tomiyama H. Intestinal metaplasia-dysplasia-carcinoma sequence of the gallbladder. Acta Pathol Jpn 1986 ; 36 : 989-997.
39) Garcia P, Manterola C, Araya JC, Villaseca M, Guzman P, Sanhueza A, et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog 2009 ; 48 : 79-89.
40) Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis : evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 2007 ; 31 : 907-913.

最近チェックした商品履歴

Loading...